SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number 001-36245
RiceBran Technologies
(Exact Name of Registrant as Specified in its Charter)

California
(State or other jurisdiction of
incorporation or organization)
 
87-0673375
(I.R.S. Employer Identification No.)
1330 Lake Robbins Drive, Suite 250
The Woodlands, TX
 (Address of Principal Executive Offices)
 
77380
(Zip Code)

(281) 675-2421
(Registrant’s telephone number, including area code)
 
None
(Former name, former address and former fiscal year, if changed since last report

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging company.  See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒

   
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule l2b-2 of the Exchange Act).  Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock, no par value per share
 
RIBT
 
The NASDAQ Capital Market

As of July 28, 2020, shares of the registrant’s common stock outstanding totaled 40,207,398.



RiceBran Technologies
Index
Form 10-Q

PART I. FINANCIAL INFORMATION
Page
 
Item 1.
3
    3
    4
    5
     6
     7
 
Item 2.
18
 
Item 3.
20
 
Item 4.
20
PART II. OTHER INFORMATION
 
 
Item 1.
20
 
Item 1A.
20
 
Item 2.
20
 
Item 3.
21
 
Item 4.
21
 
Item 5.
21
 
Item 6.
21
22

Cautionary Note about Forward-Looking Statements

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue, liquidity or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services, products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.  Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words.  The forward-looking statements contained herein reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions.  Actual results may differ materially from those projected in such forward-looking statements due to a number of factors, risks and uncertainties, including the factors that may affect future results set forth in this Current Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2019.  We disclaim any obligation to update any forward looking statements as a result of developments occurring after the date of this quarterly report.

Unless the context requires otherwise, references to “we,” “us,” “our” and “the Company” refer to RiceBran Technologies and its consolidated subsidiaries.

2

PART I. FINANCIAL INFORMATION

Item 1.
Financial Statements.

RiceBran Technologies
Condensed Consolidated Statements of Operations
Three and Six Months Ended June 30, 2020 and 2019
(Unaudited) (in thousands, except share and per share amounts)

   
Three Months Ended
   
Six Months Ended
 
   
2020
   
2019
   
2020
   
2019
 
                         
Revenues
 
$
5,903
   
$
6,219
   
$
14,233
   
$
12,583
 
Cost of goods sold
   
7,127
     
6,463
     
15,862
     
12,484
 
Gross profit (loss)
   
(1,224
)
   
(244
)
   
(1,629
)
   
99
 
Selling, general and administrative expenses
   
2,615
     
3,422
     
5,165
     
6,763
 
Operating loss
   
(3,839
)
   
(3,666
)
   
(6,794
)
   
(6,664
)
Other income (expense):
                               
Interest income
   
8
     
23
     
19
     
23
 
Interest expense
   
(76
)
   
(19
)
   
(125
)
   
(31
)
Other expense
   
(42
)
   
(3
)
   
(87
)
   
(4
)
Other income
   
-
     
6
     
5
     
6
 
Total other income (expense), net
   
(110
)
   
7
     
(188
)
   
(6
)
Loss before income taxes
   
(3,949
)
   
(3,659
)
   
(6,982
)
   
(6,670
)
Income tax benefit
   
-
     
-
     
-
     
-
 
Loss from continuing operations
   
(3,949
)
   
(3,659
)
   
(6,982
)
   
(6,670
)
Loss from discontinued operations
   
-
     
-
     
-
     
(216
)
Net loss
 
$
(3,949
)
 
$
(3,659
)
 
$
(6,982
)
 
$
(6,886
)
                                 
Basic loss per common share:
                               
Continuing operations
 
$
(0.10
)
 
$
(0.11
)
 
$
(0.17
)
 
$
(0.21
)
Discontinued operations
   
-
     
-
     
-
     
(0.01
)
Basic loss per common share
 
$
(0.10
)
 
$
(0.11
)
 
$
(0.17
)
 
$
(0.22
)
                                 
Diluted loss per common share:
                               
Continuing operations
 
$
(0.10
)
 
$
(0.11
)
 
$
(0.17
)
 
$
(0.21
)
Discontinued operations
   
-
     
-
     
-
     
(0.01
)
Diluted loss per common share
 
$
(0.10
)
 
$
(0.11
)
 
$
(0.17
)
 
$
(0.22
)
                                 
Weighted average number of shares outstanding:
         
Basic
   
40,052,163
     
33,204,332
     
40,007,660
     
31,382,927
 
Diluted
   
40,052,163
     
33,204,332
     
40,007,660
     
31,382,927
 

See Notes to Unaudited Condensed Consolidated Financial Statements

3

RiceBran Technologies
Condensed Consolidated Statements of Comprehensive Loss
Three and Six Months Ended June 30, 2020 and 2019
(Unaudited) (in thousands, except share and per share amounts)

   
Three Months Ended
   
Six Months Ended
 
   
2020
   
2019
   
2020
   
2019
 
                         
Net loss
 
$
(3,949
)
 
$
(3,659
)
 
$
(6,982
)
 
$
(6,886
)
                                 
Derivative financial instruments designated as cash flow hedges:
 
Losses arising during the period
   
(100
)
   
-
     
(100
)
   
-
 
Reclassification of losses realized to cost of goods sold
    52
      -
     
52
     
-
 
Net other comprehensive loss
   
(48
)
   
-
     
(48
)
   
-
 
                                 
Comprehensive loss
 
$
(3,997
)
 
$
(3,659
)
 
$
(7,030
)
 
$
(6,886
)

See Notes to Unaudited Condensed Consolidated Financial Statements

4

RiceBran Technologies
Condensed Consolidated Balance Sheets
(Unaudited) (in thousands, except share amounts)

   
June 30,
2020
   
December 31,
2019
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
 
$
3,347
   
$
8,444
 
Accounts receivable, net of allowance for doubtful accounts of $24 and $347
   
2,718
     
3,738
 
Inventories
   
2,009
     
898
 
Other current assets
   
1,392
     
691
 
Total current assets
   
9,466
     
13,771
 
Property and equipment, net
   
18,523
     
19,077
 
Operating lease right-of-use assets
   
2,604
     
2,752
 
Goodwill
   
3,915
     
3,915
 
Intangible assets
   
833
     
950
 
Other long-term assets
   
-
     
27
 
Total assets
 
$
35,341
   
$
40,492
 
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable
 
$
949
   
$
833
 
Commodities payable
   
198
     
829
 
Accrued salary, wages and benefits
   
1,051
     
877
 
Accrued expenses
   
473
     
884
 
Customer prepayments
   
-
     
12
 
Operating lease liabilities, current portion
   
325
     
309
 
Due under insurance premium finance agreements
   
307
     
116
 
Due under factoring agreement
   
2,053
     
1,823
 
Finance lease liabilities, current portion
   
96
     
101
 
Long-term debt, current portion
   
29
     
28
 
Total current liabilities
   
5,481
     
5,812
 
Operating lease liabilities, less current portion
   
2,474
     
2,674
 
Finance lease liabilities, less current portion
   
150
     
190
 
Long-term debt, less current portion
   
1,847
     
73
 
Total liabilities
   
9,952
     
8,749
 
Commitments and contingencies
               
Shareholders’ equity:
               
Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $225,  225 shares, issued and outstanding
   
112
     
112
 
Common stock, no par value, 150,000,000 shares authorized, 40,207,398 shares and 40,074,483 shares, issued and outstanding
   
319,487
     
318,811
 
Accumulated deficit
   
(294,162
)
   
(287,180
)
Accumulated other comprehensive loss
   
(48
)
   
-
 
Total shareholders’ equity
   
25,389
     
31,743
 
Total liabilities and shareholders’ equity
 
$
35,341
   
$
40,492
 

See Notes to Unaudited Condensed Consolidated Financial Statements

5

RiceBran Technologies
Condensed Consolidated Statements of Cash Flows
Six Months Ended June 30, 2020 and 2019
(Unaudited) (in thousands)

   
2020
   
2019
 
Cash flow from operating activities:
           
Net loss
 
$
(6,982
)
 
$
(6,886
)
Loss from discontinued operations
   
-
     
216
 
Loss from continuing operations
   
(6,982
)
   
(6,670
)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities
               
Depreciation
   
1,157
     
853
 
Amortization
   
117
     
20
 
Stock and share-based compensation
   
664
     
643
 
Loss on disposition of property and equipment
   
308
     
-
 
Other
   
(107
)
   
(2
)
Changes in operating assets and liabilities, net of impact of acquisitions:
               
Accounts receivable
   
1,090
     
(774
)
Inventories
   
(1,111
)
   
(5
)
Accounts payable and accrued expenses
   
(201
)
   
(348
)
Commodities payable
   
(631
)
   
(768
)
Other
   
(675
)
   
(398
)
Net cash used in operating activities
   
(6,371
)
   
(7,449
)
Cash flows from investing activities:
               
Purchases of property and equipment
   
(843
)
   
(2,319
)
Acquisition of MGI
   
-
     
(3,795
)
Net cash used in investing activities
   
(843
)
   
(6,114
)
Cash flows from financing activities:
               
Payments on factoring agreement
   
(14,946
)
   
-
 
Advances on factoring agreement
   
15,131
     
-
 
Advances on insurance premium finance agreements
   
506
     
418
 
Payments on insurance premium finance agreements
   
(316
)
   
(138
)
Advances on debt and finance lease liabilities
   
1,792
     
-
 
Payments on debt and finance lease liabilities
   
(62
)
   
(302
)
Proceeds from common stock warrant exercises
   
12
     
1,990
 
Proceeds from common stock option exercises
   
-
     
147
 
Proceeds from issuance of common stock and pre-funded warrant, net of issuance costs
   
-
     
11,593
 
Net cash provided by financing activities
   
2,117
     
13,708
 
Net change in cash and cash equivalents and restricted cash
 
$
(5,097
)
 
$
145
 
                 
Cash and cash equivalents and restricted cash, beginning of period
               
Cash and cash equivalents
 
$
8,444
   
$
7,044
 
Restricted cash
   
-
     
225
 
Cash and cash equivalents and restricted cash, beginning of period
   
8,444
     
7,269
 
Cash and cash equivalents and restricted cash, end of period
               
Cash and cash equivalents
   
3,347
     
7,189
 
Restricted cash
   
-
     
225
 
Cash and cash equivalents and restricted cash, end of period
   
3,347
     
7,414
 
Net change in cash and cash equivalents and restricted cash
 
$
(5,097
)
 
$
145
 
                 
Supplemental disclosures:
               
Cash paid for interest
 
$
79
   
$
43
 
Cash paid for income taxes
 
$
-
   
$
-
 

See Notes to Unaudited Condensed Consolidated Financial Statements

6

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 1. BASIS OF PRESENTATION

In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements.  The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles.

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business.

NOTE 2. BUSINESS

We are a specialty ingredient company focused on producing value-added processing and marketing of healthy, natural and nutrient dense products derived from rice and other small grains, and the by-products created in the milling of these grains. Notably, we apply our proprietary technologies to convert raw rice bran into stabilized rice bran (SRB), and high value derivative products including: RiBalance, a rice bran nutritional package derived from SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance and ProRyza, a rice bran protein-based product; and a variety of other valuable derivatives extracted from these core products.

In granular form, SRB is a food additive used in the production of products for both human and animal consumption. We believe SRB has certain inherent qualities that make it more attractive for this purpose than food additives based on the by-products of other agricultural commodities, such as corn and soybeans.  Our SRB and refined SRB products and derivatives support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods, and high-end animal nutrition.  Our target customers are natural food, food and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally.

We manufacture and distribute SRB in various granulations from four locations: two leased facilities located within supplier-owned rice mills in Arbuckle and West Sacramento, California; one company-owned facility in Mermentau, Louisiana; and our company-owned rice mill in Wynne, Arkansas.  At our Dillon, Montana facility, we produce SRB based products and derivatives that have been further refined through our proprietary processes.  Our rice mill in Wynne, Arkansas also supplies grades U.S. No. 1 and No. 2 premium long and medium white rice. We also own a grain processing facility in East Grand Forks, Minnesota, at which we mill a variety of grains which we offer to the market.

7

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Recent Accounting Guidance

Recent accounting standards not yet adopted

The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice.

In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method.  The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts.  The guidance, and subsequent guidance related to the topic, is effective for our annual and interim periods beginning in 2023 and must be adopted on a modified retrospective approach through cumulative-effect adjustment to retained earnings as of January 1, 2023.  Based on the nature of our current receivables and our credit loss history, we do not expect the adoption of the guidance to have a significant impact on our results of operations, financial position, or cash flows.

Recently adopted accounting standards

In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which, among other things, removed an exception in the guidance to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items such as discontinued operations.  We early adopted the guidance effective January 1, 2020.  Adoption of the guidance had no impact on our results of operations, financial position, or cashflows.

Reclassifications – Certain reclassifications have been made to amounts reported for the prior period to achieve consistent presentation with the current period. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.

Derivative Financial Instruments

In May 2020, we began to use derivative financial instruments to manage a portion of our risks related to commodity prices.  We do not use derivative financial instruments for trading or speculative purposes.  Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting.  Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges.  Gains and losses on derivatives designated as cash flow hedges, to the extent they are included in the assessment of effectiveness, are recorded in OCI and subsequently reclassified to cost of goods sold to offset the impact of the hedged items when they occur.  In the event it becomes probable the forecasted transaction to which a cash flow hedge relates will not occur, the derivative is terminated and the amount in accumulated OCI is recognized in earnings.  All cash flows related to derivative financial instruments are classified as operating activities in our consolidated statements of cash flows.

NOTE 4. ACQUISITION

On April 4, 2019, we acquired substantially all of the assets comprising the business of MGI Grain Processing, LLC, a Minnesota limited liability company, now conducting business as MGI Grain Incorporated (MGI). The results of MGI’s operations are included in our consolidated financial statements beginning April 4, 2019.  The following table provides unaudited pro forma information for the three months and six months ended June 30, 2019, as if the MGI acquisition had occurred January 1, 2019.

   
Three Months Ended
June 30, 2019
   
Six Months Ended
June 30, 2019
 
Revenues (in thousands)
 
$
6,277
   
$
13,783
 
Loss from continuing operations (in thousands)
 
$
(3,803
)
 
$
(6,539
)
Loss per share - continuing operations
 
$
(0.11
)
 
$
(0.21
)
Weighted average number of common shares outstanding - basic and diluted
   
33,204,332
     
31,382,927
 

8

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

No adjustments have been made in the pro forma information for synergies that are resulting or planned from the MGI acquisition.  The unaudited proforma information is not indicative of the results that may have been achieved had the companies been combined as of January 1, 2018, or of our future operating results.

NOTE 5. CASH AND CASH EQUIVALENTS

As of June 30, 2020, we have $2.0 million of cash and cash equivalents invested in a money market fund with net assets invested in U.S. Dollar denominated money market securities of domestic and foreign issuers, U.S. Government securities and repurchase agreements.  We consider all liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

We have cash on deposit in excess of federally insured limits at a bank.  We do not believe that maintaining substantially all such assets with the bank or investing in a liquid money market fund represent material risks.

NOTE 6. ACCOUNTS RECEIVABLE AND REVENUES

Amounts billed and due from our customers are classified as accounts receivable on our consolidated balance sheets and require payment on a short-term basis. Invoices are generally issued at the point control transfers and substantially all of our invoices are due within 30 days or less, however certain customers have terms of up to 120 days.  For substantially all of our contracts, control of the ordered product(s) transfers at our location.  Periodically, we require payment prior to the point in time we recognize revenue.  Amounts received from customers prior to revenue recognition on a contract are contract liabilities, are classified as customer prepayments liability on our consolidated balance sheets and are typically applied to an invoice within 30 days of the prepayment.  Revenues in the three and six months ended June 30, 2020, include less than $0.1 million in revenue unearned as of December 31, 2019.

Our accounts receivable potentially subject us to significant concentrations of credit risk.  Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals.

   
Customer
 
      A

    B

    C

% of revenues, three months ended June 30, 2020
   
10
%
   
8
%
   
3
%
% of revenues, three months ended June 30, 2019
   
10
%
   
14
%
   
1
%
                         
% of revenues, six months ended June 30, 2020
   
9
%
   
13
%
   
2
%
% of revenues, six  months ended June 30, 2019
   
10
%
   
16
%
   
1
%
                         
% of accounts receivable, as of June 30, 2020
   
14
%
   
32
%
   
8
%
% of accounts receivable, as of December 31, 2019
   
10
%
   
31
%
   
10
%

In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S.  The following table presents revenues by product line (in thousands).

   
Three Months Ended June 30
   
Six Months Ended June 30
 
   
2020
   
2019
   
2020
   
2019
 
Food
 
$
3,967
   
$
4,365
   
$
10,159
   
$
9,112
 
Animal nutrition
 

1,936
     
1,854
     
4,074
     
3,471
 
Revenues
 
$
5,903
   
$
6,219
   
$
14,233
   
$
12,583
 

9

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 7. INVENTORIES

The following table details the components of inventories (in thousands).

   
June 30,
2020
   
December 31,
2019
 
Finished goods
 
$
1,799
   
$
698
 
Raw materials
   
80
     
90
 
Packaging
   
130
     
110
 
Inventories
 
$
2,009
   
$
898
 

NOTE 8. LEASES

The components of lease expense and cash flows from leases (in thousands) follow.

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2020
   
2019
   
2020
   
2019
 
Finance lease cost:
                       
Amortization of right-of use assets, included in cost of goods sold
 
$
20
   
$
14
   
$
41
   
$
18
 
Interest on lease liabilities
   
4
     
2
     
8
     
4
 
Operating lease cost, included in selling, general and administrative expenses:
                               
Fixed leases cost
   
131
     
131
     
261
     
261
 
Variable lease cost
   
33
     
32
     
48
     
64
 
Short-term lease cost
   
-
     
7
     
3
     
16
 
Total lease cost
 
$
188
   
$
186
   
$
361
   
$
363
 
                                 
Cash paid for amounts included in the measurement of lease liabilities:
                               
Operating cash flows from finance leases
 
$
4
   
$
3
   
$
8
   
$
5
 
Operating cash flows from operating leases
 
$
131
   
$
131
   
$
261
   
$
261
 
Financing cash flows from finance leases
 
$
20
   
$
20
   
$
46
   
$
31
 

As of June 30, 2020, variable lease payments do not depend on a rate or index.  As of June 30, 2020, property and equipment, net, includes $0.3 million of finance lease right-of-use-assets, with an original cost of $0.4 million.

As of June 30, 2020, we do not believe it is certain that we will exercise any renewal options.  The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of June 30, 2020, follows.

   
Operating
Leases
   
Finance
Leases
 
Remaining leases terms (in years)
   
3.3-12.7
     
0.6-4.0
 
Weighted average remaining lease terms (in years)
   
7.3
     
2.9
 
Discount rates
   
6.3%-9.0
%
   
4.3%-7.3
%
Weighted average discount rate
   
7.6
%
   
5.8
%

10

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

Maturities of lease liabilities as of June 30, 2020, follows (in thousands).

   
Operating
Leases
   
Finance
Leases
 
2020 (six months ended December 31, 2020)
  $
232
    $
62
 
2021
   
536
     
91
 
2022
   
548
     
68
 
2023
   
528
     
38
 
2024
   
428
     
11
 
Thereafter
   
1,469
     
-
 
Total lease payments
   
3,741
     
270
 
Amounts representing interest
   
(942
)
   
(24
)
Present value of lease obligations
 
$
2,799
   
$
246
 

NOTE 9. DEBT

In the three and six months ended June 30, 2020, we financed amounts owed for annual insurance premiums under financing agreements, due in monthly installments of principal and interest through January 2021, at interest rates of 4.7% to 5.5% per year.

In October 2019, we entered into a factoring agreement which provides for a $7.0 million credit facility with a lender.  We may only borrow to the extent we have qualifying accounts receivable as defined in the agreement.  The facility has an initial two-year term and automatically renews for successive annual periods, unless proper termination notice is given.  We paid a $0.2 million facility fee upon inception of the agreement which is amortizing to interest expense on a straight-line basis over two years.  We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances and a service fee on average net funds borrowed.  During the three and six months ended June 30, 2020, we expensed $0.1 million and $0.2 million of interest and fees under the agreement, fees incurred averaged 4.4% (exclusive of deferred cost amortization) and interest averaged 3.2% of the amounts outstanding under the facility.  During the three and six months ended June 30, 2020, outstanding borrowings under the agreement averaged $2.9 million and $2.0 million per day.  Amortization of debt issuance costs in the three and six months ended June 30, 2020, was less than $0.1 million.  The lender has the right to demand repayment of the advances at any time.  The lender has a security interest in our personal property assets.

Due under factoring agreement consists of the following (in thousands).

   
June 30,
2020
   
December 31,
2019
 
Borrowings outstanding
 
$
2,174
   
$
1,989
 
Debt issuance costs, net
   
(121
)
   
(166
)
Due under factoring agreement
 
$
2,053
   
$
1,823
 

11

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

Long-term debt consists of the following (in thousands).

   
June 30,
2020
   
December 31,
2019
 
Payroll Protection Program note - Dated April 2020.  Interest accrues at an annual rate of 1.0%.
           
Due in monthly installments from November 2020 to April 2022, unless forgiven as described below.
 
$
1,792
    $
-
 
Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year , which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition.  Payable in monthly installments. Expire at dates ranging through 2022.
   
47
     
62
 
Equipment note - Dated December 2019.  Due in monthly installments through December 2024.
               
Interest accrues at the effective discount rate of 9.3% per year .
   
37
     
39
 
Total long term debt
 
$
1,876
   
$
101
 

In April 2020, we received $1.8 million on an SBA Payroll Protection Program loan as provided for in the Coronavirus Aid, Relief and Economic Security Act (CARES), enacted into U.S. law in March 2020.  Under certain conditions, the loan and accrued interest are forgivable after eight weeks as long as we use the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains payroll levels.  The amount of loan forgiveness will be reduced if we terminate employees or reduce salaries during the eight-week period.  The unforgiven portion of the loan is payable over two years at an interest rate of 1.0%, with a deferral of payments for the first six months.  We intend to use the proceeds for purposes consistent with the program.  While we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, we cannot assure that we will be eligible for forgiveness of the loan, in whole or in part.

In July 2020, we entered into a mortgage agreement with a lender pursuant to a promissory note. Under this promissory note we may borrow up to the lesser of (i) $2.0 million or (ii) 65% of the appraised value of our rice mill in Wynne, Arkansas which is securing our obligations under the promissory note.  Interest accrues at an annual rate which is the greater of 11.0% above the lender’s prime rate and 14.3%.  In addition, we will incur a facility fee equal to 1.0% of the amount of each advance under the promissory note.  We may request advances under the agreement through October 2020.  The principal advances must be repaid in monthly installments ending in June 2022. Any obligations that we incur under the promissory note will be secured by certain real property and personal property assets.

NOTE 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS

In June 2020, shareholders approved, and we filed an amendment to our articles of incorporation increasing our authorized shares of common stock from 50,000,000 to 150,000,000.

A summary of equity activity follows (in thousands, except share amounts).

   
Shares
                     
Accumulated
Other
       
   
Preferred
Series G
   
Common
   
Preferred
Stock
   
Common
Stock
   
Accumulated
Deficit
   
Comprehensive
Loss
   
Equity
 
Balance, December 31, 2019
   
225
     
40,074,483
   
$
112
   
$
318,811
   
$
(287,180
)
 
$
-
   
$
31,743
 
Common stock awards under equity incentive plans
   
-
     
17,534
     
-
     
312
     
-
     
-
     
312
 
Net loss
   
-
     
-
     
-
     
-
     
(3,033
)
   
-
     
(3,033
)
Balance, March 31, 2020
   
225
     
40,092,017
   
$
112
   
$
319,123
   
$
(290,213
)
 
$
-
   
$
29,022
 
Common stock awards under equity incentive plans
   
-
     
16,500
     
-
     
316
     
-
     
-
     
316
 
Commn stock issued to vendors
   
-
     
31,304
     
-
     
36
     
-
     
-
     
36
 
Exercise of common stock warrants
   
-
     
67,577
     
-
     
12
     
-
     
-
     
12
 
Other comprehensive loss
   
-
     
-
     
-
     
-
     
-
     
(48
)
   
(48
)
Net loss
   
-
     
-
     
-
     
-
     
(3,949
)
   
-
     
(3,949
)
Balance, June 30, 2020
   
225
     
40,207,398
   
$
112
   
$
319,487
   
$
(294,162
)
 
$
(48
)
 
$
25,389
 

12

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

   
Shares
                   
   
Preferred
Series G
   
Common
   
Preferred
Stock
   
Common
Stock
   
Accumulated
Deficit
   
Equity
 
Balance, December 31, 2018
   
405
     
29,098,207
   
$
201
   
$
296,739
   
$
(273,229
)
 
$
23,711
 
Proceeds from sale of common stock and prefunded warrant, net of costs
   
-
     
3,046,668
     
-
     
11,593
     
-
     
11,593
 
Common stock awards under equity incentive plans
   
-
     
36,881
     
-
     
364
     
-
     
364
 
Exercise of common stock warrants
   
-
     
600,000
     
-
     
1,980
     
-
     
1,980
 
Conversion of preferred stock into common stock
   
(180
)
   
170,818
     
(89
)
   
89
     
-
     
-
 
Exercise of common stock options
   
-
     
77,078
     
-
     
60
     
-
     
60
 
Other
   
-
     
-
     
-
     
28
     
-
     
28
 
Net loss
   
-
     
-
     
-
     
-
     
(3,227
)
   
(3,227
)
Balance, March 31, 2019
   
225
     
33,029,652
     
112
     
310,853
     
(276,456
)
   
34,509
 
Exercise of prefunded warrant
   
-
     
1,003,344
     
-
     
10
     
-
     
10
 
Common stock awards under equity incentive plans
   
-
     
134,984
     
-
     
219
     
-
     
219
 
Exercise of common stock options
   
-
     
78,734
     
-
     
87
     
-
     
87
 
Other
   
-
     
-
     
-
     
32
     
-
     
32
 
Net loss
   
-
     
-
     
-
     
-
     
(3,659
)
   
(3,659
)
Balance, June 30, 2019
   
225
     
34,246,714
   
$
112
   
$
311,201
   
$
(280,115
)
 
$
31,198
 

On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million through B. Riley FBR, Inc, as sales agent.  The issuance and sale, if any, of our common stock under the agreement will be made pursuant to our effective “shelf” registration statement on Form S-3. No sales were made to date under this agreement. We have deferred $0.1 million of legal expenses and other costs related to the offering which are included in other current assets in our consolidated balance sheets as of June 30, 2020.

Share-based compensation by type of award follows (in thousands).

   
Three Months Ended
 
   
June 30, 2020
   
March 31, 2020
 
Common stock, vested at issuance and nonvested at issuance
 
$
95
   
$
105
 
Stock options
   
99
     
85
 
Restricted stock units
   
122
     
122
 
Compensation expense related to common stock awards issued under equity incentive plan
 
$
316
   
$
312
 

In the three months ended March 31, 2020, we issued 17,534 shares of common stock, vested at issuance, to a consultant at a grant date fair value of $1.11 per share and recognized $0.1 million of expense for shares of common stock vesting during the period.

In the three months ended June 30, 2020, under the equity incentive plan, we issued 16,500 shares of common stock, vested at June 30, 2020, at a grant date fair value or $1.16 per shares and (ii) recognized $0.1 million of expense for shares of common stock vesting during the period.  As of June 30, 2020, there was no shares of nonvested common stock outstanding.  In the three months ended June 30, 2020, we issued 31,304 shares of common stock to a vendor, vested at June 30, 2020, at a grant date fair value or $1.14 per share.

Stock option activity for the six months ended June 30, 2020, follows.

   
Shares
Under
Options
     
Weighted
Average
Exercise
Price
   
Weighted
Average
Grant
Date Fair
Value
   
Weighted
Average
Remaining
Contractual
Life (Years)
 
Outstanding at December 31, 2019
   
996,009
   
$
3.23
           
8.1
 
Granted
   
653,004
     
1.22
   
$
0.73
     
10.0
 
Forfeited
   
(125,173
)
   
4.74
             
7.2
 
Outstanding at March 31, 2020
   
1,523,840
     
2.24
             
8.8
 
Forfeited
   
(77,357
)
   
4.28
             
7.2
 
Outstanding at June 30, 2020
   
1,446,483
   
$
2.13
             
8.6
 

13

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

Stock options granted in the three months ended March 31, 2020, each vest and become exercisable in annual installments ending four years from the date of grant and were valued using methods and assumptions comparable to those for our 2019 stock option grants.

Restricted stock unit (RSU) activity for the six months ended June 30, 2020, follows.

   
RSU Shares
Issued to
Employees
and
Directors
   
Unrecognized
Stock
Compensation
(in thousands)
   
Weighted
Average
Expense
Period
(Years)
 
Nonvested at December 31, 2019
   
1,148,062
   
$
377
     
1.4
 
Cancelled
   
(625,000
)
   
-
         
Forfeited (1)
   
(175,000
)
   
(142
)
       
Expensed (2)
   
-
     
(122
)
       
Nonvested at March 31, 2020
   
348,062
     
113
     
1.2
 
Granted to Directors (3)
   
477,018
     
426
         
Forfeited
   
(30,000
)
   
(24
)
       
Vested (4)
   
(115,904
)
   
-
         
Expensed
   
-
     
(122
)
       
Nonvested at June 30, 2020 (5)(6)
   
679,176
   
$
393
     
0.8
 


(1)
In the three months ended March 31, 2020, we reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares.

(2)
We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares.

(3)
The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.

(4)
Represents shares of common stock subject to RSUs which were vested when granted.

(5)
RSUs for a total of 361,114 shares of common stock vest in June 2021, and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies.

(6)
A total of 318,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days.  Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 31,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 95,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 190,837 shares the date the vesting price equals or exceeds $15.00 per share.  Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence.  The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.

Warrant activity for the six months ended June 30, 2020, follows.

   
Shares
Under
Warrants
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
 Life (Years)
 
                   
Outstanding, December 31, 2019
   
7,532,280
   
$
1.32
     
1.9
 
Expired
   
(265,000
)
   
5.25
     
-
 
Outstanding, March 31, 2020
   
7,267,280
     
1.18
     
1.7
 
Cash exercised
   
(12,948
)
   
0.96
     
-
 
Cashless exercised (1)
   
(215,740
)
   
0.96
     
-
 
Expired
   
(392,676
)
   
4.60
     
-
 
Outstanding, June 30, 2020 (2)
   
6,645,916
   
$
0.98
     
1.7
 


(1)
In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.

(2)
Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature.  As of June 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an average exercise price of $5.25 per share.  If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise.  If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.

14

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 11. INCOME TAXES

Our tax expense for the three and six months ended June 30, 2020 and 2019, differs from the tax expense computed by applying the U.S. statutory tax rate to net loss from continuing operations before income taxes as no tax benefits were recorded for tax losses generated in the U.S.  As of June 30, 2020, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards.  We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur.

Based on an analysis of tax positions taken on income tax returns filed, we have determined no material liabilities related to uncertain income tax positions exist.  Although we believe the amounts reflected in our tax returns substantially comply with applicable U.S. federal, state, and foreign tax regulations, the respective taxing authorities may take contrary positions based on their interpretation of the law.  A tax position successfully challenged by a taxing authority could result in an adjustment to our provision or benefit for income taxes in the period in which a final determination is made.

CARES, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds and modifications to the net interest deduction limitations. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment.  Except for the impact of the loan we received under the act, see Note 9, we do not anticipate that the act will have a material impact on our financial position, results of operations or cash flows.

NOTE 12. LOSS PER SHARE (EPS)

Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends.  Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses.

Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive.  The dilutive effects of outstanding options, warrants, nonvested shares of common stock and nonvested restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method.  The dilutive effects of the outstanding preferred stock are calculated using the if-converted method.

Below are reconciliations of the numerators and denominators in the EPS computations.

   
Three Months Ended June 30
   
Six Months Ended June 30
 
   
2020
   
2019
   
2020
   
2019
 
NUMERATOR (in thousands):
                       
Basic and diluted - loss from continuing operations
 
$
(3,949
)
 
$
(3,659
)
 
$
(6,982
)
 
$
(6,670
)
                                 
DENOMINATOR:
                               
Weighted average number of shares of shares of common stock outstanding
   
40,041,888
     
33,204,332
     
40,002,522
     
31,382,927
 
Weighted average number of shares of common stock underlying vested restricted stock units
   
10,275
     
-
     
5,138
     
-
 
Basic EPS - weighted average number of shares outstanding
   
40,052,163
     
33,204,332
     
40,007,660
     
31,382,927
 
Effect of dilutive securities outstanding
   
-
     
-
     
-
     
-
 
Diluted EPS - weighted average number of shares outstanding
   
40,052,163
     
33,204,332
     
40,007,660
     
31,382,927
 

15

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

No effects of potentially dilutive securities outstanding during the three and six months ended June 30, 2020 and 2019, were included in the calculation of diluted EPS for the three and six months ended June 30, 2020 and 2019 because to do so would be anti-dilutive as a results of our loss from continuing operations.  Potentially dilutive securities outstanding during the periods included our outstanding convertible preferred stock, options, warrants, nonvested restricted stock units and nonvested stock.  Those potentially dilutive securities, further described in Note 10, could potentially dilute EPS in the future.

NOTE 13. DERIVATIVE FINANCIAL INSTRUMENTS

As of June 30, 2020, our outstanding derivative financial instruments consist of commodity futures which trade on a major exchange.  As of June 30, 2020, other current assets include a $0.5 million receivable representing our margin account with a broker.  We are potentially exposed to credit risk under the futures but not for the notional amounts.  We are exposed to credit risk to the extent the open futures are in an asset position.  At June 30, 2020, the fair value of open futures was a negative $48 thousand (recorded in accumulated OCI) and, therefore, we had no credit risk associated with those open derivative financial instruments.

NOTE 14. FAIR VALUE MEASUREMENTS

Derivative financial instruments are carried at fair value, on a recurring basis, in accumulated OCI, and fair value is based on the quoted prices of the financial instruments (Level 1 measurements).  The fair value of cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, commodities payable and short-term debt approximated their carrying value due to shorter maturities.  As of June 30, 2020, the fair values of our operating lease liabilities was approximately $0.1 million higher than their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).  As of June 30, 2020, the fair values of our long-term debt and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).

NOTE 15. COMMITMENTS AND CONTINGENCIES

Employment Contracts and Severance Payments

In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions.  While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions.  No amounts have been recorded in our financial statements with respect to any obligations under such agreements.

We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control.  In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control.

Legal Matters

From time to time we are involved in litigation incidental to the conduct of our business.  These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations.  When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Defense costs are expensed as incurred and are included in professional fees.  While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations, except for a contract dispute settled in July 2020 for $0.2 million. In the three months ended June 30, 2020, we included $0.2 million in cost of goods sold and as of June 30, 2020, included a $0.2 million liability in our consolidated financial statements for this matter.  The liability was net against accounts receivable under a right of offset.

16

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 16. RELATED PARTY TRANSACTIONS

Our director, Ari Gendason, is an employee and senior vice president and chief investment officer of Continental Grain Company (CGC).  As of the date of this filing, CGC owns approximately 26.5% of our outstanding common stock.  We have agreed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors.  In March 2019, we issued and sold to CGC 666,667 shares of common stock at a purchase price of $3.00 per share and a prefunded warrant exercisable into 1,003,344 shares of common stock for $2.99 per share, in a private placement.  The prefunded warrant had an exercise price of $0.01 per share and was immediately exercisable; however, we had to obtain approval from our shareholders before CGC could exercise the prefunded warrant to the extent such exercise would result in the holder owning in excess of 19.99% of our common shares outstanding.  CGC exercised the entire prefunded warrant automatically when our shareholders approved the exercise in June 2019.

NOTE 17.  TRANSACTIONS WITH EMPLOYEES

During the six months ended June 30, 2019, and three months ended March 31, 2019, we paid $1.4 million to entities owned by our former employee, Wayne Wilkison.  As of June 30, 2020, and December 31, 2019, no amounts were owed to these entities.

NOTE 18. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS

On July 27, 2020, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we have failed to comply with the minimum bid price requirement of Nasdaq List Rule 5550(a)(2).  Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00.  To regain compliance with this listing rule, the closing bid price of our common stock must be at least $1.00 for 10 consecutive business days.  Nasdaq rules allow for a compliance period of 180 calendar days, or until January 25, 2021 in which to regain compliance.  If this appears unlikely as January 25, 2021 approaches, we are committed to taking actions that would enable us to regain compliance, including, if necessary, completing a reverse split of our common stock to increase its share price above the $1.00 minimum bid price.

NOTE 19. SUBSEQUENT EVENTS

On August 11, 2020, RiceBran Technologies and Mr. Brent Rystrom entered into a separation and release agreement which provides that, effective August 14, 2020, Mr. Rystrom resigns as our employee, chief executive officer, and director.  We will retain Mr. Rystrom as a consultant through December 31, 2020, and Mr. Rystrom will receive medical and insurance benefits during this period.

On August 11, 2020, our board of directors appointed Peter G. Bradley to the role of executive chairman effective August 14, 2020.  In this role, Mr. Bradley will oversee our day-to-day operations as well as coordinate a review of strategic alternatives.  Mr. Bradley is a global business leader with more than 23 years of experience as an executive in various food and ingredients businesses.  Most recently, Mr. Bradley has been a principal at Ingredient Insights, a strategic consultant focused on food ingredients and is currently an operating partner at Arbor Investments, a private equity firm that focuses exclusively on acquiring premier companies in the food, beverage and related industries.

On August 11, 2020, our board of directors appointed Brent Rosenthal to serve in the capacity of lead independent director effective August 14, 2020.

17

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations

Unless otherwise noted, amounts and percentages for all periods discussed below reflect the results of operations and financial condition from our continuing operations.

Three Months Ended June 30, 2020 Compared to Three Months Ended June 30, 2019

Revenues decreased $0.3 million in the second quarter of 2020 compared to the second quarter of 2019.  The decrease in revenue year over year was due to lower revenues from our RiceBran operations partially offset by an increase in revenue from MGI Grain (MGI).  Revenue for Golden Ridge Rice Mill (Golden Ridge) was also down modestly from a year ago, as higher daily production levels were offset by a slowdown in production at the mill for six weeks in the second quarter as we were not able to acquire sufficient rough rice to mill at an economical price.  By type, animal feed product revenues increased 4%, while food product revenues decreased by 9%. The increase in animal feed products revenue was a shift in product revenue from food to animal feed products at RBT. The decrease in food product revenue reflects the product mix at RBT combined with lower revenues at the Golden Ridge facility.

We experienced a gross loss of $1.2 million in the second quarter of 2020 compared to a gross loss of $0.2 million in the second quarter of 2019.  The increase in gross loss was primarily attributable to negative operating leverage from our RiceBran operations as a result of lower volumes versus a year ago.  Gross losses from Golden Ridge also increased from the same period a year ago due to higher input commodity prices and negative operating leverage from a slowdown in production at the mill for six weeks in the second quarter.

Selling, general and administrative (SG&A) expenses were $2.6 million in the second quarter of 2020, compared to $3.4 million in the second quarter of 2019, a decrease of $0.8 million.  The decline in SG&A expense was primarily related to benefits from initiatives enacted in the first quarter of 2020 to reduce overall SG&A costs.

Other expense increased $0.1 million in the second quarter of 2020 compared to the second quarter of 2019.  This increase was primarily due to higher fees and interest expense related to the increased average outstanding balance of our factoring facility, a new facility entered in to in the fourth quarter of 2019.

Six Months Ended June 30, 2020, Compared to Six Months Ended June 30, 2019

Revenues increased $1.6 million, or 13.1%, in the first half of 2020 compared to the first half of 2019.  The increase in revenue year over year was due to higher revenues from Golden Ridge and MGI, offset by a decline in revenue from our RiceBran operations.  MGI was acquired in April 2019 and, therefore, our revenues included no MGI revenue in the first quarter of 2019.  By type, animal feed product revenues increased by 17%, while food product revenues increased 11% year over year, primarily due to higher sales of finished rice from Golden Ridge, and the additional revenue from MGI for the first three months of 2020. During the first six months of 2020, RBT operations provided higher animal food revenue; however, this was offset by lower revenue from human food products.

We experienced a gross loss of $1.6 million in the first half of 2020, compared to a gross profit of $0.1 million in the first half of 2019.  The decline in gross profit was primarily attributable to higher losses from Golden Ridge due to sub-par milling yields, an unfavorable spread on certain contracts due to higher input commodity prices as a result of delays in fulfillment, and negative operating leverage from a slowdown in production at the mill for six weeks in the second quarter.  Gross profits were also negatively impacted by negative operating leverage from our RiceBran operations in the second quarter.  This decline was offset in part by a higher gross profit contribution from MGI.

SG&A expenses were $5.2 million in the first six months of 2020, compared to $6.8 million in the first six months of 2019, a decrease of $1.6 million.  The decline in SG&A expense was primarily related to the absence of approximately $0.3 million in costs associated with our acquisition of Golden Ridge in the comparable period a year ago, lower legal and outside accounting fees, as well the initial benefits from initiatives to reduce overall SG&A costs.

Other expense increased $0.2 million in the first six months of 2020 compared to the first six months of 2019.  This increase was primarily due to higher fees and interest expense related to the increased average outstanding balance of our factoring facility, a new facility entered in to in the fourth quarter of 2019.

COVID-19 Assessment

The United States is experiencing an outbreak of a novel coronavirus (COVID-19), which has been declared a “pandemic” by the World Health Organization.

18

The COVID-19 pandemic has become a worldwide health crisis that is adversely affecting the economies and financial markets of many countries, which we expect may adversely affect the demand for our products.   This pandemic also poses the risk that we or our customers, suppliers and other business partners may be disrupted or prevented from conducting business activities for certain periods of time, the durations of which are uncertain.  However, we are not able to estimate the exact magnitude of the impact of such developments on our business.  The extent of the impact of COVID-19 on our business and financial results will depend on future developments, including the duration and spread of the outbreak within the markets in which we operate, including the related impact on our customers’ spending, all of which is highly uncertain.

In April 2020, we applied for, and received, a $1.8 million SBA Paycheck Protection Program loan as discussed further in Note 9 of the Notes to Unaudited Condensed Consolidated Financial Statements.  We anticipate the funds from this loan will enable us to maintain our current workforce during any economic disruptions to our business as a result of the COVID-19 outbreak.

We currently do not expect any of our facilities to be subject to government-mandated closures, and we have informed our customers that at this time we anticipate operating throughout the COVID-19 outbreak. To date, our employees have been reporting to work, either remotely or in-person, without any material changes in attendance or productivity due to the COVID-19 outbreak.

Liquidity and Capital Resources

We used $6.4 million in operating cash during the 2020 first half.  In the first half of 2020 we used operating cash to (i) increase our inventories in anticipation of a seasonal shut down of our Louisiana facilities for part of the second and third quarters, (ii) fund a $0.5 million margin account, carried in other current assets in our consolidated balance sheets, in connection with the commodities hedging program we began in the second quarter of 2020, and (iii) pay down commodities payable $0.6 million with no offset for incoming purchases due to lack of rough rice. We experienced a $1.1 million reduction in accounts receivable associated with the decrease in revenues at the end of the second quarter of 2020. We paid $0.8 million of capital expenditures in the first half of 2020.  We funded our working capital needs in the first half of 2020, primarily with a reduction in our cash reserves and proceeds from the PPP loan.

On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million.  As of the date of this filing, we have not sold any shares of our common stock pursuant to this program. As discussed further in Note 9 of the Notes to Unaudited Condensed Consolidated Financial Statements, in April 2020, we were approved for a $1.8 million SBA Payroll Protection Program loan (PPP Loan) and in July 2020, we secured a mortgage of up to $2.0 million on our rice mill in Wynne, Arkansas.  Management believes the COVID-19 outbreak has created general market uncertainty which may currently limit the company’s ability to seek external sources of funding for investment initiatives and/or general operations.  However, with these sources of funds, as of the date of this filing, management believes we have sufficient capital reserves and borrowing capacity to maintain our workforce and fund the operations of the business through the remainder of the COVID-19 outbreak and until such time as market conditions normalize.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, other than employee contracts, that have or are likely to have a current or future material effect on our financial condition, changes in financial condition, revenue, expenses, results of operations, liquidity, capital expenditures, or capital resources.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.  The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures on the date of the financial statements.  On an ongoing basis, we evaluate the estimates, including, but not limited to, those related to revenue recognition.  We use authoritative pronouncements, historical experience and other assumptions as the basis for making judgments.  Actual results could differ from those estimates.

Recent Accounting Pronouncements

See Note 3 in the Notes to Unaudited Condensed Consolidated Financial Statements for further discussion.

19

Item 3.
Quantitative and Qualitative Disclosures about Market Risk

Not applicable

Item 4.
Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosures.

We evaluated, with the participation of our chief executive officer, and chief financial officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q.  Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

During the most recently completed fiscal quarter, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.
Legal Proceedings

We are involved in or subject to, or may become involved in or subject to, routine litigation, claims, disputes, proceedings and investigations in the ordinary course of business.  While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position, results of operations or cash flows.  We record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated.

Item 1A.
Risk Factors

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, which could materially affect our business, financial condition, liquidity or future results.  The risks described in our Annual Report on Form 10-K are not the only risks facing our company.  Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, liquidity or future results.

Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended June 30, 2020, we issued the securities described below without registration under the Securities Act.  Unless otherwise indicated below, the securities were issued pursuant to the private placement exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended.

In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon cashless exercise of warrants for the purchase of up to 215,740 shares of common stock at an exercise price of $0.96 per share.

In the three months ended June 30, 2020, we issued 12,948 shares of common stock upon the cash exercise of a warrant for the purchase of up to 12,948 shares of common stock at an exercise price of $0.96 per share.

On June 30, 2020, we issued 31,304 shares of common stock to a vendor, vested at June 30, 2020, at a grant date fair value or $1.14 per share.

20

Item 3.
Defaults upon Senior Securities

None

Item 4.
Mine Safety Disclosures

None

Item 5.
Other Information

None

Item 6.
Exhibits

The following exhibits are attached hereto and filed herewith:

 
 
 
 
Incorporated by Reference
 
 
Exhibit
Number
 
Exhibit Description
 
Form
 
File No.
 
Exhibit
Number
 
Filing/Effective
Date
 
Filed
Here-with
                         
 
Certificate of Amendment of Articles of Incorporation filed with the Secretary of State of California on June 18, 2020
                 
X
 
Promissory Note dated as of April 15, 2020
 
8-K
 
001-36245
 
10.1
 
April 16, 2020
   
 
Amended and Restated 2014 Equity Incentive Plan (2)
 
8-K
 
001-36245
 
10.2
 
July 17, 2020
   
 
Form of Award of Deferred and Restricted Stock Units for 2014 Equity Incentive Plan (2)
 
8-K
 
001-36245
 
10.3
 
July 17, 2020
   
 
Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
             
 
X
 
Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
             
 
X
 
Certification by CEO and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
             
 
X
101.INS (1)
 
XBRL Instance Document
 
             
 
X
101.SCH (1)
 
XBRL Taxonomy Extension Schema Document
 
             
 
X
101.CAL (1)
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
             
 
X
101.DEF (1)
 
XBRL Taxonomy Extension Calculation Definition Linkbase Document
 
             
 
X
101.LAB (1)
 
XBRL Taxonomy Extension Calculation Label Linkbase Document
 
             
 
X
101.PRE (1)
 
XBRL Taxonomy Extension Calculation Presentation Linkbase Document
 
             
 
X


(1)
XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

(2)
Indicates a management contract or compensatory plan, contract or arrangement.

21

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated:  August 12, 2020
 
 
 
 
 
 
/s/ Brent R. Rystrom
 
 
Brent R. Rystrom
 
Director and Chief Executive Officer

 
/s/ Todd T. Mitchell
 
 
Todd T. Mitchell
 
Chief Financial Officer


22


Exhibit 3.1

CERTIFICATE OF AMENDMENT OF
ARTICLES OF INCORPORATION OF
RICEBRAN TECHNOLOGIES

The undersigned, Brent R. Rystrom and Reed Anderson hereby certify that:

ONE:          Brent R. Rystrom is the duly elected President of RiceBran Technologies and Reed Anderson is the duly elected Secretary of RiceBran Technologies, a California corporation (“Corporation”).

TWO:        Article Three of the Articles of Incorporation of the Corporation shall be amended to read in full as follows:

ARTICLE THREE

“This Corporation is hereafter authorized to issue two (2) classes of shares of stock designated respectively “Common Stock” and “Preferred Stock.”  The total number of shares of Common Stock that this Corporation is authorized to issue is one hundred fifty million (150,000,000) and the total number of shares of Preferred Stock that this Corporation is authorized to issue is twenty million (20,000,000).

The Preferred Stock may be divided into such number of series as the board of directors may determine.  The board of directors is authorized to determine and alter the rights, preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock, and to fix the number of shares of any series of Preferred Stock and the designation of any such series of Preferred Stock.  The board of directors, within the limits and restrictions stated in any resolution or resolutions of the board of directors originally fixing the number of shares constituting any series, may increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series subsequent to the issue of shares of that series.”

THREE:     The foregoing amendment of the Articles of Incorporation has been approved by the board of directors of the Company.

FOUR:       The foregoing amendment of the Articles of Incorporation has been approved by the holders of the requisite number of shares of the corporation in accordance with Sections 902 and 903 of the California Corporations Code.  The total number of outstanding shares entitled to vote with respect to the foregoing amendment was 40,074,483 shares of Common Stock.  The number of shares voting in favor of the foregoing amendment equaled or exceeded the vote required, such required vote being a majority of the outstanding shares of Common Stock.


We further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

Date:
June 17, 2020

/s/ Brent R. Rystrom
 
Brent R. Rystrom, President
 

/s/ Reed Anderson
 
Reed Anderson, Secretary
 





Exhibit 31.1

Certification of Principal Executive Officer
 Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Brent R. Rystrom, certify that:

1)
I have reviewed this quarterly report on Form 10-Q of RiceBran Technologies;

2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report was prepared;


b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5)
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):


a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s disclosure internal control over financial reporting.
 
Dated:  August 12, 2020
/s/ Brent R. Rystrom
 
     
 
Name: Brent R. Rystrom
 
Title: Director and Chief Executive Officer
 



Exhibit 31.2

Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd T. Mitchell, certify that:

1)
I have reviewed this quarterly report on Form 10-Q of RiceBran Technologies;

2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report was prepared;


b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5)
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):


a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s disclosure internal control over financial reporting.

Dated:  August 12, 2020
/s/ Todd T. Mitchell
 
   
 
Name: Todd T. Mitchell
 
Title: Chief Financial Officer




Exhibit 32.1

Certification of Principal Executive Officer and Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
In connection with the Quarterly Report on Form 10-Q of RiceBran Technologies (the Company) for the period ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Company.
 
Dated:  August 12, 2020
   
     
 
/s/ Brent R. Rystrom
 
 
Brent Rystrom
 
Director and Chief Executive Officer
 
 
/s/ Todd T. Mitchell
 
 
Todd T. Mitchell
 
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-Q.




v3.20.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2020
Jul. 28, 2020
Cover [Abstract]    
Entity Registrant Name RiceBran Technologies  
Entity Central Index Key 0001063537  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   40,207,398
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2020  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q2  
Entity Address, State or Province TX  
v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Condensed Consolidated Statements of Operations (Unaudited) [Abstract]        
Revenues $ 5,903 $ 6,219 $ 14,233 $ 12,583
Cost of goods sold 7,127 6,463 15,862 12,484
Gross profit (loss) (1,224) (244) (1,629) 99
Selling, general and administrative expenses 2,615 3,422 5,165 6,763
Operating loss (3,839) (3,666) (6,794) (6,664)
Other income (expense):        
Interest income 8 23 19 23
Interest expense (76) (19) (125) (31)
Other expense (42) (3) (87) (4)
Other income 0 6 5 6
Total other income (expense), net (110) 7 (188) (6)
Loss before income taxes (3,949) (3,659) (6,982) (6,670)
Income tax benefit 0 0 0 0
Loss from continuing operations (3,949) (3,659) (6,982) (6,670)
Loss from discontinued operations 0 0 0 (216)
Net loss $ (3,949) $ (3,659) $ (6,982) $ (6,886)
Basic loss per common share:        
Continuing operations (in dollars per share) $ (0.10) $ (0.11) $ (0.17) $ (0.21)
Discontinued operations (in dollars per share) 0 0 0 (0.01)
Basic loss per common share (in dollars per share) (0.10) (0.11) (0.17) (0.22)
Diluted loss per common share:        
Continuing operations (in dollars per share) (0.10) (0.11) (0.17) (0.21)
Discontinued operations (in dollars per share) 0 0 0 (0.01)
Diluted loss per common share (in dollars per share) $ (0.10) $ (0.11) $ (0.17) $ (0.22)
Weighted average number of shares outstanding:        
Basic (in shares) 40,052,163 33,204,332 40,007,660 31,382,927
Diluted (in shares) 40,052,163 33,204,332 40,007,660 31,382,927
v3.20.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) [Abstract]        
Net loss $ (3,949) $ (3,659) $ (6,982) $ (6,886)
Derivative financial instruments designated as cash flow hedges:        
Losses arising during the period (100) 0 (100) 0
Reclassification of losses realized to cost of goods sold 52 0 52 0
Net other comprehensive loss (48) 0 (48) 0
Comprehensive loss $ (3,997) $ (3,659) $ (7,030) $ (6,886)
v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 3,347 $ 8,444
Accounts receivable, net of allowance for doubtful accounts of $24 and $347 2,718 3,738
Inventories 2,009 898
Other current assets 1,392 691
Total current assets 9,466 13,771
Property and equipment, net 18,523 19,077
Operating lease right-of-use assets 2,604 2,752
Goodwill 3,915 3,915
Intangible assets 833 950
Other long-term assets 0 27
Total assets 35,341 40,492
Current liabilities:    
Accounts payable 949 833
Commodities payable 198 829
Accrued salary, wages and benefits 1,051 877
Accrued expenses 473 884
Customer prepayments 0 12
Operating lease liabilities, current portion 325 309
Due under insurance premium finance agreements 307 116
Due under factoring agreement 2,053 1,823
Finance lease liabilities, current portion 96 101
Long-term debt, current portion 29 28
Total current liabilities 5,481 5,812
Operating lease liabilities, less current portion 2,474 2,674
Finance lease liabilities, less current portion 150 190
Long-term debt, less current portion 1,847 73
Total liabilities 9,952 8,749
Commitments and contingencies
Shareholders' equity:    
Common stock, no par value, 150,000,000 shares authorized, 40,207,398 shares and 40,074,483 shares, issued and outstanding 319,487 318,811
Accumulated deficit (294,162) (287,180)
Accumulated other comprehensive loss (48) 0
Total shareholders' equity 25,389 31,743
Total liabilities and shareholders' equity 35,341 40,492
Series G Convertible Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $225, 225 shares, issued and outstanding $ 112 $ 112
v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Accounts receivable, allowance for doubtful accounts $ 24 $ 347
Shareholders' equity:    
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 40,207,398 40,074,483
Common stock, shares outstanding (in shares) 40,207,398 40,074,483
Series G Convertible Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, shares authorized (in shares) 3,000 3,000
Preferred stock, stated value $ 225 $ 225
Convertible preferred stock, shares issued (in shares) 225 225
Convertible preferred stock, shares outstanding (in shares) 225 225
v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Cash flow from operating activities:    
Net loss $ (6,982) $ (6,886)
Loss from discontinued operations 0 216
Loss from continuing operations (6,982) (6,670)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:    
Depreciation 1,157 853
Amortization 117 20
Stock and share-based compensation 664 643
Loss on disposition of property and equipment 308 0
Other (107) (2)
Changes in operating assets and liabilities, net of impact of acquisitions:    
Accounts receivable 1,090 (774)
Inventories (1,111) (5)
Accounts payable and accrued expenses (201) (348)
Commodities payable (631) (768)
Other (675) (398)
Net cash used in operating activities (6,371) (7,449)
Cash flows from investing activities:    
Purchases of property and equipment (843) (2,319)
Acquisition of MGI 0 (3,795)
Net cash used in investing activities (843) (6,114)
Cash flows from financing activities:    
Payments on factoring agreement (14,946) 0
Advances on factoring agreement 15,131 0
Advances on insurance premium finance agreements 506 418
Payments on insurance premium finance agreements (316) (138)
Advances on debt and finance lease liabilities 1,792 0
Payments on debt and finance lease liabilities (62) (302)
Proceeds from common stock warrant exercises 12 1,990
Proceeds from common stock option exercises 0 147
Proceeds from issuance of common stock and pre-funded warrant, net of issuance costs 0 11,593
Net cash provided by financing activities 2,117 13,708
Net change in cash and cash equivalents and restricted cash (5,097) 145
Cash and cash equivalents and restricted cash, beginning of period    
Cash and cash equivalents 8,444 7,044
Restricted cash 0 225
Cash and cash equivalents and restricted cash, beginning of period 8,444 7,269
Cash and cash equivalents and restricted cash, end of period    
Cash and cash equivalents 3,347 7,189
Restricted cash 0 225
Cash and cash equivalents and restricted cash, end of period 3,347 7,414
Supplemental disclosures:    
Cash paid for interest 79 43
Cash paid for income taxes $ 0 $ 0
v3.20.2
BASIS OF PRESENTATION
6 Months Ended
Jun. 30, 2020
BASIS OF PRESENTATION [Abstract]  
BASIS OF PRESENTATION
NOTE 1. BASIS OF PRESENTATION

In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements.  The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles.

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business.
v3.20.2
BUSINESS
6 Months Ended
Jun. 30, 2020
BUSINESS [Abstract]  
BUSINESS
NOTE 2. BUSINESS

We are a specialty ingredient company focused on producing value-added processing and marketing of healthy, natural and nutrient dense products derived from rice and other small grains, and the by-products created in the milling of these grains. Notably, we apply our proprietary technologies to convert raw rice bran into stabilized rice bran (SRB), and high value derivative products including: RiBalance, a rice bran nutritional package derived from SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance and ProRyza, a rice bran protein-based product; and a variety of other valuable derivatives extracted from these core products.

In granular form, SRB is a food additive used in the production of products for both human and animal consumption. We believe SRB has certain inherent qualities that make it more attractive for this purpose than food additives based on the by-products of other agricultural commodities, such as corn and soybeans.  Our SRB and refined SRB products and derivatives support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods, and high-end animal nutrition.  Our target customers are natural food, food and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally.

We manufacture and distribute SRB in various granulations from four locations: two leased facilities located within supplier-owned rice mills in Arbuckle and West Sacramento, California; one company-owned facility in Mermentau, Louisiana; and our company-owned rice mill in Wynne, Arkansas.  At our Dillon, Montana facility, we produce SRB based products and derivatives that have been further refined through our proprietary processes.  Our rice mill in Wynne, Arkansas also supplies grades U.S. No. 1 and No. 2 premium long and medium white rice.  We also own a grain processing facility in East Grand Forks, Minnesota, at which we mill a variety of grains which we can offer to the market.
v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Recent Accounting Guidance

Recent accounting standards not yet adopted

The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice.

In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method.  The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts.  The guidance, and subsequent guidance related to the topic, is effective for our annual and interim periods beginning in 2023 and must be adopted on a modified retrospective approach through cumulative-effect adjustment to retained earnings as of January 1, 2023.  Based on the nature of our current receivables and our credit loss history, we do not expect the adoption of the guidance to have a significant impact on our results of operations, financial position, or cash flows.

Recently adopted accounting standards

In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes(Topic 740): Simplifying the Accounting for Income Taxes which, among other things, removed an exception in the guidance to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items such as discontinued operations.  We early adopted the guidance effective January 1, 2020.  Adoption of the guidance had no impact on our results of operations, financial position, or cashflows.

Reclassifications – Certain reclassifications have been made to amounts reported for the prior period to achieve consistent presentation with the current period. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.

Derivative Financial Instruments

In May 2020, we began to use derivative financial instruments to manage a portion of our risks related to commodity prices.  We do not use derivative financial instruments for trading or speculative purposes.  Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting.  Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges.  Gains and losses on derivatives designated as cash flow hedges, to the extent they are included in the assessment of effectiveness, are recorded in OCI and subsequently reclassified to cost of goods sold to offset the impact of the hedged items when they occur.  In the event it becomes probable the forecasted transaction to which a cash flow hedge relates will not occur, the derivative is terminated and the amount in accumulated OCI is recognized in earnings.  All cash flows related to derivative financial instruments are classified as operating activities in our consolidated statements of cash flows.
v3.20.2
ACQUISITION
6 Months Ended
Jun. 30, 2020
ACQUISITION [Abstract]  
ACQUISITION
NOTE 4. ACQUISITION

On April 4, 2019, we acquired substantially all of the assets comprising the business of MGI Grain Processing, LLC, a Minnesota limited liability company, now conducting business as MGI Grain Incorporated (MGI). The results of MGI’s operations are included in our consolidated financial statements beginning April 4, 2019.  The following table provides unaudited pro forma information for the three months and six months ended June 30, 2019, as if the MGI acquisition had occurred January 1, 2019.

  
Three Months Ended
June 30, 2019
  
Six Months Ended
June 30, 2019
 
Revenues (in thousands)
 
$
6,277
  
$
13,783
 
Loss from continuing operations (in thousands)
 
$
(3,803
)
 
$
(6,539
)
Loss per share - continuing operations
 
$
(0.11
)
 
$
(0.21
)
Weighted average number of common shares outstanding - basic and diluted
  
33,204,332
   
31,382,927
 

No adjustments have been made in the pro forma information for synergies that are resulting or planned from the MGI acquisition.  The unaudited proforma information is not indicative of the results that may have been achieved had the companies been combined as of January 1, 2018, or of our future operating results.
v3.20.2
CASH AND CASH EQUIVALENTS
6 Months Ended
Jun. 30, 2020
CASH AND CASH EQUIVALENTS [Abstract]  
CASH AND CASH EQUIVALENTS
NOTE 5. CASH AND CASH EQUIVALENTS

As of June 30, 2020, we have $2.0 million of cash and cash equivalents invested in a money market fund with net assets invested in U.S. Dollar denominated money market securities of domestic and foreign issuers, U.S. Government securities and repurchase agreements.  We consider all liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

We have cash on deposit in excess of federally insured limits at a bank.  We do not believe that maintaining substantially all such assets with the bank or investing in a liquid money market fund represent material risks.
v3.20.2
ACCOUNTS RECEIVABLE AND REVENUES
6 Months Ended
Jun. 30, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]  
ACCOUNTS RECEIVABLE AND REVENUES
NOTE 6. ACCOUNTS RECEIVABLE AND REVENUES

Amounts billed and due from our customers are classified as accounts receivable on our consolidated balance sheets and require payment on a short-term basis. Invoices are generally issued at the point control transfers and substantially all of our invoices are due within 30 days or less, however certain customers have terms of up to 120 days.  For substantially all of our contracts, control of the ordered product(s) transfers at our location.  Periodically, we require payment prior to the point in time we recognize revenue.  Amounts received from customers prior to revenue recognition on a contract are contract liabilities, are classified as customer prepayments liability on our consolidated balance sheets and are typically applied to an invoice within 30 days of the prepayment.  Revenues in the three and six months ended June 30, 2020, include less than $0.1 million in revenue unearned as of December 31, 2019.

Our accounts receivable potentially subject us to significant concentrations of credit risk.  Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals.

  
Customer
 
   A

  B

  C

% of revenues, three months ended June 30, 2020
  
10
%
  
8
%
  
3
%
% of revenues, three months ended June 30, 2019
  
10
%
  
14
%
  
1
%
             
% of revenues, six months ended June 30, 2020
  
9
%
  
13
%
  
2
%
% of revenues, six  months ended June 30, 2019
  
10
%
  
16
%
  
1
%
             
% of accounts receivable, as of June 30, 2020
  
14
%
  
32
%
  
8
%
% of accounts receivable, as of December 31, 2019
  
10
%
  
31
%
  
10
%

In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S.  The following table presents revenues by product line (in thousands).

  
Three Months Ended June 30
  
Six Months Ended June 30
 
  
2020
  
2019
  
2020
  
2019
 
Food
 
$
3,967
  
$
4,365
  
$
10,159
  
$
9,112
 
Animal nutrition
 

1,936
   
1,854
   
4,074
   
3,471
 
Revenues
 
$
5,903
  
$
6,219
  
$
14,233
  
$
12,583
 
v3.20.2
INVENTORIES
6 Months Ended
Jun. 30, 2020
INVENTORIES [Abstract]  
INVENTORIES
NOTE 7. INVENTORIES

The following table details the components of inventories (in thousands).

  
June 30,
2020
  
December 31,
2019
 
Finished goods
 
$
1,799
  
$
698
 
Raw materials
  
80
   
90
 
Packaging
  
130
   
110
 
Inventories
 
$
2,009
  
$
898
 
v3.20.2
LEASES
6 Months Ended
Jun. 30, 2020
LEASES [Abstract]  
LEASES
NOTE 8. LEASES

The components of lease expense and cash flows from leases (amounts in thousands) follow.

  
Three Months Ended June 30,
  
Six Months Ended June 30,
 
  
2020
  
2019
  
2020
  
2019
 
Finance lease cost:
            
Amortization of right-of use assets, included in cost of goods sold
 
$
20
  
$
14
  
$
41
  
$
18
 
Interest on lease liabilities
  
4
   
2
   
8
   
4
 
Operating lease cost, included in selling, general and administrative expenses:
                
Fixed leases cost
  
131
   
131
   
261
   
261
 
Variable lease cost
  
33
   
32
   
48
   
64
 
Short-term lease cost
  
-
   
7
   
3
   
16
 
Total lease cost
 
$
188
  
$
186
  
$
361
  
$
363
 
                 
Cash paid for amounts included in the measurement of lease liabilities:
                
Operating cash flows from finance leases
 
$
4
  
$
3
  
$
8
  
$
5
 
Operating cash flows from operating leases
 
$
131
  
$
131
  
$
261
  
$
261
 
Financing cash flows from finance leases
 
$
20
  
$
20
  
$
46
  
$
31
 

As of June 30, 2020, variable lease payments do not depend on a rate or index.  As of June 30, 2020, property and equipment, net, includes $0.3 million of finance lease right-of-use-assets, with an original cost of $0.4 million.

As of June 30, 2020, we do not believe it is certain that we will exercise any renewal options.  The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of June 30, 2020, follows.

  
Operating
Leases
  
Finance
Leases
 
Remaining leases terms (in years)
  
3.3-12.7
   
0.6-4.0
 
Weighted average remaining lease terms (in years)
  
7.3
   
2.9
 
Discount rates
  
6.3%-9.0
%
  
4.3%-7.3
%
Weighted average discount rate
  
7.6
%
  
5.8
%

Maturities of lease liabilities as of June 30, 2020, follows (in thousands).

  
Operating
Leases
  
Finance
Leases
 
2020 (six months ended December 31, 2020)
 $
232
  $
62
 
2021
  
536
   
91
 
2022
  
548
   
68
 
2023
  
528
   
38
 
2024
  
428
   
11
 
Thereafter
  
1,469
   
-
 
Total lease payments
  
3,741
   
270
 
Amounts representing interest
  
(942
)
  
(24
)
Present value of lease obligations
 
$
2,799
  
$
246
 
v3.20.2
DEBT
6 Months Ended
Jun. 30, 2020
DEBT [Abstract]  
DEBT
NOTE 9. DEBT

In the three and six months ended June 30, 2020, we financed amounts owed for annual insurance premiums under financing agreements, due in monthly installments of principal and interest through January 2021, at interest rates of 4.7% to 5.5% per year.

In October 2019, we entered into a factoring agreement which provides for a $7.0 million credit facility with a lender.  We may only borrow to the extent we have qualifying accounts receivable as defined in the agreement.  The facility has an initial two-year term and automatically renews for successive annual periods, unless proper termination notice is given.  We paid a $0.2 million facility fee upon inception of the agreement which is amortizing to interest expense on a straight-line basis over two years.  We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances and a service fee on average net funds borrowed.  During the three and six months ended June 30, 2020, we expensed $0.1 million and $0.2 million of interest and fees under the agreement, fees incurred averaged 4.4% (exclusive of deferred cost amortization) and interest averaged 3.2% of the amounts outstanding under the facility.  During the three and six months ended June 30, 2020, outstanding borrowings under the agreement averaged $2.9 million and $2.0 million per day.  Amortization of debt issuance costs in the three and six months ended June 30, 2020, was less than $0.1 million.  The lender has the right to demand repayment of the advances at any time.  The lender has a security interest in our personal property assets.

Due under factoring agreement consists of the following (in thousands).

  
June 30,
2020
  
December 31,
2019
 
Borrowings outstanding
 
$
2,174
  
$
1,989
 
Debt issuance costs, net
  
(121
)
  
(166
)
Due under factoring agreement
 
$
2,053
  
$
1,823
 

Long-term debt consists of the following (in thousands).

  
June 30,
2020
  
December 31,
2019
 
Payroll Protection Program note - Dated April 2020.  Interest accrues at an annual rate of 1.0%.
      
Due in monthly installments from November 2020 to April 2022, unless forgiven as described below.
 
$
1,792
  $
-
 
Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year , which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition.  Payable in monthly installments. Expire at dates ranging through 2022.
  
47
   
62
 
Equipment note - Dated December 2019.  Due in monthly installments through December 2024.
        
Interest accrues at the effective discount rate of 9.3% per year .
  
37
   
39
 
Total long term debt
 
$
1,876
  
$
101
 

In April 2020, we received $1.8 million on an SBA Payroll Protection Program loan as provided for in the Coronavirus Aid, Relief and Economic Security Act (CARES), enacted into U.S. law in March 2020.  Under certain conditions, the loan and accrued interest are forgivable after eight weeks as long as we use the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains payroll levels.  The amount of loan forgiveness will be reduced if we terminate employees or reduce salaries during the eight-week period.  The unforgiven portion of the loan is payable over two years at an interest rate of 1.0%, with a deferral of payments for the first six months.  We intend to use the proceeds for purposes consistent with the program.  While we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, we cannot assure that we will be eligible for forgiveness of the loan, in whole or in part.

In July 2020, we entered into a mortgage agreement with a lender pursuant to which we may borrow up to the lesser of (i) $2.0 million or (ii) 65% of the appraised value of our rice mill in Wynne, Arkansas which is securing the agreement.  Interest accrues at an annual rate which is the greater of 11.0% above the lender’s prime rate and 14.3%.  In addition, we will incur a facility fee equal to 1.0% of the amount of each advance under the agreement.  We may request advances under the agreement through October 2020.  The principal advances must be repaid in monthly installments ending in June 2022. Any obligations that we incur under the promissory note will be secured by certain real property and personal property assets.
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS
6 Months Ended
Jun. 30, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]  
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS
NOTE 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS

In June 2020, shareholders approved, and we filed an amendment to our articles of incorporation increasing our authorized shares of common stock from 50,000,000 to 150,000,000.

A summary of equity activity follows (in thousands, except share amounts).

  
Shares
           
Accumulated
Other
    
  
Preferred
Series G
  
Common
  
Preferred
Stock
  
Common
Stock
  
Accumulated
Deficit
  
Comprehensive
Loss
  
Equity
 
Balance, December 31, 2019
  
225
   
40,074,483
  
$
112
  
$
318,811
  
$
(287,180
)
 
$
-
  
$
31,743
 
Common stock awards under equity incentive plans
  
-
   
17,534
   
-
   
312
   
-
   
-
   
312
 
Net loss
  
-
   
-
   
-
   
-
   
(3,033
)
  
-
   
(3,033
)
Balance, March 31, 2020
  
225
   
40,092,017
  
$
112
  
$
319,123
  
$
(290,213
)
 
$
-
  
$
29,022
 
Common stock awards under equity incentive plans
  
-
   
16,500
   
-
   
316
   
-
   
-
   
316
 
Commn stock issued to vendors
  
-
   
31,304
   
-
   
36
   
-
   
-
   
36
 
Exercise of common stock warrants
  
-
   
67,577
   
-
   
12
   
-
   
-
   
12
 
Other comprehensive loss
  
-
   
-
   
-
   
-
   
-
   
(48
)
  
(48
)
Net loss
  
-
   
-
   
-
   
-
   
(3,949
)
  
-
   
(3,949
)
Balance, June 30, 2020
  
225
   
40,207,398
  
$
112
  
$
319,487
  
$
(294,162
)
 
$
(48
)
 
$
25,389
 

  
Shares
          
  
Preferred
Series G
  
Common
  
Preferred
Stock
  
Common
Stock
  
Accumulated
Deficit
  
Equity
 
Balance, December 31, 2018
  
405
   
29,098,207
  
$
201
  
$
296,739
  
$
(273,229
)
 
$
23,711
 
Proceeds from sale of common stock and prefunded warrant, net of costs
  
-
   
3,046,668
   
-
   
11,593
   
-
   
11,593
 
Common stock awards under equity incentive plans
  
-
   
36,881
   
-
   
364
   
-
   
364
 
Exercise of common stock warrants
  
-
   
600,000
   
-
   
1,980
   
-
   
1,980
 
Conversion of preferred stock into common stock
  
(180
)
  
170,818
   
(89
)
  
89
   
-
   
-
 
Exercise of common stock options
  
-
   
77,078
   
-
   
60
   
-
   
60
 
Other
  
-
   
-
   
-
   
28
   
-
   
28
 
Net loss
  
-
   
-
   
-
   
-
   
(3,227
)
  
(3,227
)
Balance, March 31, 2019
  
225
   
33,029,652
   
112
   
310,853
   
(276,456
)
  
34,509
 
Exercise of prefunded warrant
  
-
   
1,003,344
   
-
   
10
   
-
   
10
 
Common stock awards under equity incentive plans
  
-
   
134,984
   
-
   
219
   
-
   
219
 
Exercise of common stock options
  
-
   
78,734
   
-
   
87
   
-
   
87
 
Other
  
-
   
-
   
-
   
32
   
-
   
32
 
Net loss
  
-
   
-
   
-
   
-
   
(3,659
)
  
(3,659
)
Balance, June 30, 2019
  
225
   
34,246,714
  
$
112
  
$
311,201
  
$
(280,115
)
 
$
31,198
 

On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million through B. Riley FBR, Inc, as sales agent.  The issuance and sale, if any, of our common stock under the agreement will be made pursuant to our effective “shelf” registration statement on Form S-3. No sales made to date under this agreement  We have deferred $0.1 million of legal expenses and other costs related to the offering which are included in other current assets in our consolidated balance sheets as of June 30, 2020.

Share-based compensation by type of award follows (in thousands).

  
Three Months Ended
 
  
June 30, 2020
  
March 31, 2020
 
Common stock, vested at issuance and nonvested at issuance
 
$
95
  
$
105
 
Stock options
  
99
   
85
 
Restricted stock units
  
122
   
122
 
Compensation expense related to common stock awards issued under equity incentive plan
 
$
316
  
$
312
 

In the three months ended March 31, 2020, we issued 17,534 shares of common stock, vested at issuance, to a consultant at a grant date fair value of $1.11 per share and recognized $0.1 million of expense for shares of common stock vesting during the period.

In the three months ended June 30, 2020, under the equity incentive plan, we issued 16,500 shares of common stock, vested at June 30, 2020, at a grant date fair value or $1.16 per shares and (ii) recognized $0.1 million of expense for shares of common stock vesting during the period.  As of June 30, 2020, there was no shares of nonvested common stock outstanding.  In the three months ended June 30, 2020, we issued 31,304 shares of common stock to a vendor, vested at June 30, 2020, at a grant date fair value or $1.14 per share.

Stock option activity for the six months ended June 30, 2020, follows.

  
Shares
Under
Options
   
Weighted
Average
Exercise
Price
  
Weighted
Average
Grant
Date Fair
Value
  
Weighted
Average
Remaining
Contractual
Life (Years)
 
Outstanding at December 31, 2019
  
996,009
  
$
3.23
      
8.1
 
Granted
  
653,004
   
1.22
  
$
0.73
   
10.0
 
Forfeited
  
(125,173
)
  
4.74
       
7.2
 
Outstanding at March 31, 2020
  
1,523,840
   
2.24
       
8.8
 
Forfeited
  
(77,357
)
  
4.28
       
7.2
 
Outstanding at June 30, 2020
  
1,446,483
  
$
2.13
       
8.6
 

Stock options granted in the three months ended March 31, 2020, each vest and become exercisable in annual installments ending four years from the date of grant and were valued using methods and assumptions comparable to those for our 2019 stock option grants.

Restricted stock unit (RSU) activity for the six months ended June 30, 2020, follows.

  
RSU Shares
Issued to
Employees
and
Directors
  
Unrecognized
Stock
Compensation
(in thousands)
  
Weighted
Average
Expense
Period
(Years)
 
Nonvested at December 31, 2019
  
1,148,062
  
$
377
   
1.4
 
Cancelled
  
(625,000
)
  
-
     
Forfeited (1)
  
(175,000
)
  
(142
)
    
Expensed (2)
  
-
   
(122
)
    
Nonvested at March 31, 2020
  
348,062
   
113
   
1.2
 
Granted to Directors (3)
  
477,018
   
426
     
Forfeited
  
(30,000
)
  
(24
)
    
Vested (4)
  
(115,904
)
  
-
     
Expensed
  
-
   
(122
)
    
Nonvested at June 30, 2020 (5)(6)
  
679,176
  
$
393
   
0.8
 


(1)
In the three months ended March 31, 2020, we reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares.

(2)
We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares.

(3)
The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.

(4)
Represents shares of common stock subject to RSUs which were vested when granted.

(5)
RSUs for a total of 361,114 shares of common stock vest in June 2021, and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies.

(6)
A total of 318,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days.  Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 31,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 95,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 190,837 shares the date the vesting price equals or exceeds $15.00 per share.  Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence.  The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.

Warrant activity for the six months ended June 30, 2020, follows.

  
Shares
Under
Warrants
  
Weighted
Average
Exercise
Price
  
Weighted
Average
Remaining
Contractual
 Life (Years)
 
          
Outstanding, December 31, 2019
  
7,532,280
  
$
1.32
   
1.9
 
Expired
  
(265,000
)
  
5.25
   
-
 
Outstanding, March 31, 2020
  
7,267,280
   
1.18
   
1.7
 
Cash exercised
  
(12,948
)
  
0.96
   
-
 
Cashless exercised (1)
  
(215,740
)
  
0.96
   
-
 
Expired
  
(392,676
)
  
4.60
   
-
 
Outstanding, June 30, 2020 (2)
  
6,645,916
  
$
0.98
   
1.7
 


(1)
In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.

(2)
Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature.  As of June 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an average exercise price of $5.25 per share.  If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise.  If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.
v3.20.2
INCOME TAXES
6 Months Ended
Jun. 30, 2020
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 11. INCOME TAXES

Our tax expense for the three and six months ended June 30, 2020 and 2019, differs from the tax expense computed by applying the U.S. statutory tax rate to net loss from continuing operations before income taxes as no tax benefits were recorded for tax losses generated in the U.S.  As of June 30, 2020, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards.  We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur.

Based on an analysis of tax positions taken on income tax returns filed, we have determined no material liabilities related to uncertain income tax positions exist.  Although we believe the amounts reflected in our tax returns substantially comply with applicable U.S. federal, state, and foreign tax regulations, the respective taxing authorities may take contrary positions based on their interpretation of the law.  A tax position successfully challenged by a taxing authority could result in an adjustment to our provision or benefit for income taxes in the period in which a final determination is made.

CARES, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds and modifications to the net interest deduction limitations. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment.  Except for the impact of the loan we received under the act, see Note 9, we do not anticipate that the act will have a material impact on our financial position, results of operations or cash flows.
v3.20.2
LOSS PER SHARE (EPS)
6 Months Ended
Jun. 30, 2020
LOSS PER SHARE (EPS) [Abstract]  
LOSS PER SHARE (EPS)
NOTE 12. LOSS PER SHARE (EPS)

Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends.  Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses.

Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive.  The dilutive effects of outstanding options, warrants, nonvested shares of common stock and nonvested restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method.  The dilutive effects of the outstanding preferred stock are calculated using the if-converted method.

Below are reconciliations of the numerators and denominators in the EPS computations.

  
Three Months Ended June 30
  
Six Months Ended June 30
 
  
2020
  
2019
  
2020
  
2019
 
NUMERATOR (in thousands):
            
Basic and diluted - loss from continuing operations
 
$
(3,949
)
 
$
(3,659
)
 
$
(6,982
)
 
$
(6,670
)
                 
DENOMINATOR:
                
Weighted average number of shares of shares of common stock outstanding
  
40,041,888
   
33,204,332
   
40,002,522
   
31,382,927
 
Weighted average number of shares of common stock underlying vested restricted stock units
  
10,275
   
-
   
5,138
   
-
 
Basic EPS - weighted average number of shares outstanding
  
40,052,163
   
33,204,332
   
40,007,660
   
31,382,927
 
Effect of dilutive securities outstanding
  
-
   
-
   
-
   
-
 
Diluted EPS - weighted average number of shares outstanding
  
40,052,163
   
33,204,332
   
40,007,660
   
31,382,927
 

No effects of potentially dilutive securities outstanding during the three and six months ended June 30, 2020 and 2019, were included in the calculation of diluted EPS for the three and six months ended June 30, 2020 and 2019 because to do so would be anti-dilutive as a results of our loss from continuing operations.  Potentially dilutive securities outstanding during the periods included our outstanding convertible preferred stock, options, warrants, nonvested restricted stock units and nonvested stock.  Those potentially dilutive securities, further described in Note 10, could potentially dilute EPS in the future.
v3.20.2
DERIVATIVE FINANCIAL INSTRUMENTS
6 Months Ended
Jun. 30, 2020
DERIVATIVE FINANCIAL INSTRUMENTS [Abstract]  
DERIVATIVE FINANCIAL INSTRUMENTS
NOTE 13. DERIVATIVE FINANCIAL INSTRUMENTS

As of June 30, 2020, our outstanding derivative financial instruments consist of commodity futures which trade on a major exchange.  As of June 30, 2020, other current assets include a $0.5 million receivable representing our margin account with a broker.  We are potentially exposed to credit risk under the futures but not for the notional amounts.  We are exposed to credit risk to the extent the open futures are in an asset position.  At June 30, 2020, the fair value of open futures was a negative $48 thousand (recorded in accumulated OCI) and, therefore, we had no credit risk associated with those open derivative financial instruments.
v3.20.2
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2020
FAIR VALUE MEASUREMENTS [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 14. FAIR VALUE MEASUREMENTS

Derivative financial instruments are carried at fair value, on a recurring basis, in accumulated OCI, and fair value is based on the quoted prices of the financial instruments (Level 1 measurements).  The fair value of cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, commodities payable and short-term debt approximated their carrying value due to shorter maturities.  As of June 30, 2020, the fair values of our operating lease liabilities was approximately $0.1 million higher than their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).  As of June 30, 2020, the fair values of our long-term debt and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).
v3.20.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2020
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 15. COMMITMENTS AND CONTINGENCIES

Employment Contracts and Severance Payments

In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions.  While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions.  No amounts have been recorded in our financial statements with respect to any obligations under such agreements.

We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control.  In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control.

Legal Matters

From time to time we are involved in litigation incidental to the conduct of our business.  These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations.  When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Defense costs are expensed as incurred and are included in professional fees.  While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations, except for a contract dispute settled in July 2020 for $0.2 million.   In the three months ended June 30, 2020, we included $0.2 million in cost of goods sold and as of June 30, 2020, included a $0.2 million liability in our consolidated financial statements for this matter.  The liability was net against accounts receivable under a right of offset.
v3.20.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2020
RELATED PARTY TRANSACTIONS [Abstract]  
RELATED PARTY TRANSACTIONS
NOTE 16. RELATED PARTY TRANSACTIONS

Our director, Ari Gendason, is an employee and senior vice president and chief investment officer of Continental Grain Company (CGC).  As of the date of this filing, CGC owns approximately 26.5% of our outstanding common stock.  We have agreed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors.  In March 2019, we issued and sold to CGC 666,667 shares of common stock at a purchase price of $3.00 per share and a prefunded warrant exercisable into 1,003,344 shares of common stock for $2.99 per share, in a private placement.  The prefunded warrant had an exercise price of $0.01 per share and was immediately exercisable; however, we had to obtain approval from our shareholders before CGC could exercise the prefunded warrant to the extent such exercise would result in the holder owning in excess of 19.99% of our common shares outstanding.  CGC exercised the entire prefunded warrant automatically when our shareholders approved the exercise in June 2019.
v3.20.2
TRANSACTIONS WITH EMPLOYEES
6 Months Ended
Jun. 30, 2020
TRANSACTIONS WITH EMPLOYEES [Abstract]  
TRANSACTIONS WITH EMPLOYEES
NOTE 17.  TRANSACTIONS WITH EMPLOYEES

During the six months ended June 30, 2019, and three months ended March 31, 2019, we paid $1.4 million to entities owned by our former employee, Wayne Wilkison.  As of June 30, 2020, and December 31, 2019, no amounts were owed to these entities.
v3.20.2
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS
6 Months Ended
Jun. 30, 2020
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]  
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS
NOTE 18. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS

On July 27, 2020, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we have failed to comply with the minimum bid price requirement of Nasdaq List Rule 5550(a)(2).  Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00.  To regain compliance with this listing rule, the closing bid price of our common stock must be at least $1.00 for 10 consecutive business days.  Nasdaq rules allow for a compliance period of 180 calendar days, or until January 25, 2021 in which to regain compliance.  If this appears unlikely as January 25, 2021 approaches, we are committed to taking actions that would enable us to regain compliance, including, if necessary, completing a reverse split of our common stock to increase its share price above the $1.00 minimum bid price.
v3.20.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2020
SUBSEQUENT EVENTS [Abstract]  
SUBSEQUENT EVENTS
NOTE 19. SUBSEQUENT EVENTS

On August 11, 2020, RiceBran Technologies and Mr. Brent Rystrom entered into a separation and release agreement which provides that, effective August 14, 2020, Mr. Rystrom resigns as our employee, chief executive officer, and director.  We will retain Mr. Rystrom as a consultant through December 31, 2020, and Mr. Rystrom will receive medical and insurance benefits during this period.

On August 11, 2020, our board of directors appointed Peter G. Bradley to the role of executive chairman effective August 14, 2020.  In this role, Mr. Bradley will oversee our day-to-day operations as well as coordinate a review of strategic alternatives.  Mr. Bradley is a global business leader with more than 23 years of experience as an executive in various food and ingredients businesses.  Most recently, Mr. Bradley has been a principal at Ingredient Insights, a strategic consultant focused on food ingredients and is currently an operating partner at Arbor Investments, a private equity firm that focuses exclusively on acquiring premier companies in the food, beverage and related industries.

On August 11, 2020, our board of directors appointed Brent Rosenthal to serve in the capacity of lead independent director effective August 14, 2020.
v3.20.2
BASIS OF PRESENTATION (Policies)
6 Months Ended
Jun. 30, 2020
BASIS OF PRESENTATION [Abstract]  
Basis of Presentation
In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements.  The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles.

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business.
v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Recent Accounting Guidance
Recent Accounting Guidance

Recent accounting standards not yet adopted

The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice.

In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method.  The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts.  The guidance, and subsequent guidance related to the topic, is effective for our annual and interim periods beginning in 2023 and must be adopted on a modified retrospective approach through cumulative-effect adjustment to retained earnings as of January 1, 2023.  Based on the nature of our current receivables and our credit loss history, we do not expect the adoption of the guidance to have a significant impact on our results of operations, financial position, or cash flows.

Recently adopted accounting standards

In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes(Topic 740): Simplifying the Accounting for Income Taxes which, among other things, removed an exception in the guidance to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items such as discontinued operations.  We early adopted the guidance effective January 1, 2020.  Adoption of the guidance had no impact on our results of operations, financial position, or cashflows.
Reclassifications
Reclassifications – Certain reclassifications have been made to amounts reported for the prior period to achieve consistent presentation with the current period. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.
Derivative Financial Instruments
Derivative Financial Instruments

In May 2020, we began to use derivative financial instruments to manage a portion of our risks related to commodity prices.  We do not use derivative financial instruments for trading or speculative purposes.  Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting.  Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges.  Gains and losses on derivatives designated as cash flow hedges, to the extent they are included in the assessment of effectiveness, are recorded in OCI and subsequently reclassified to cost of goods sold to offset the impact of the hedged items when they occur.  In the event it becomes probable the forecasted transaction to which a cash flow hedge relates will not occur, the derivative is terminated and the amount in accumulated OCI is recognized in earnings.  All cash flows related to derivative financial instruments are classified as operating activities in our consolidated statements of cash flows.
v3.20.2
ACQUISITION (Tables)
6 Months Ended
Jun. 30, 2020
MGI Grain Processing LLC [Member]  
Business Acquisition [Line Items]  
Pro Forma Financial Information
The following table provides unaudited pro forma information for the three months and six months ended June 30, 2019, as if the MGI acquisition had occurred January 1, 2019.

  
Three Months Ended
June 30, 2019
  
Six Months Ended
June 30, 2019
 
Revenues (in thousands)
 
$
6,277
  
$
13,783
 
Loss from continuing operations (in thousands)
 
$
(3,803
)
 
$
(6,539
)
Loss per share - continuing operations
 
$
(0.11
)
 
$
(0.21
)
Weighted average number of common shares outstanding - basic and diluted
  
33,204,332
   
31,382,927
 
v3.20.2
ACCOUNTS RECEIVABLE AND REVENUES (Tables)
6 Months Ended
Jun. 30, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]  
Concentrations of Risk
Our accounts receivable potentially subject us to significant concentrations of credit risk.  Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals.

  
Customer
 
   A

  B

  C

% of revenues, three months ended June 30, 2020
  
10
%
  
8
%
  
3
%
% of revenues, three months ended June 30, 2019
  
10
%
  
14
%
  
1
%
             
% of revenues, six months ended June 30, 2020
  
9
%
  
13
%
  
2
%
% of revenues, six  months ended June 30, 2019
  
10
%
  
16
%
  
1
%
             
% of accounts receivable, as of June 30, 2020
  
14
%
  
32
%
  
8
%
% of accounts receivable, as of December 31, 2019
  
10
%
  
31
%
  
10
%
Revenues by Product Line
In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S.  The following table presents revenues by product line (in thousands).

  
Three Months Ended June 30
  
Six Months Ended June 30
 
  
2020
  
2019
  
2020
  
2019
 
Food
 
$
3,967
  
$
4,365
  
$
10,159
  
$
9,112
 
Animal nutrition
 

1,936
   
1,854
   
4,074
   
3,471
 
Revenues
 
$
5,903
  
$
6,219
  
$
14,233
  
$
12,583
 
v3.20.2
INVENTORIES (Tables)
6 Months Ended
Jun. 30, 2020
INVENTORIES [Abstract]  
Components of Inventories
The following table details the components of inventories (in thousands).

  
June 30,
2020
  
December 31,
2019
 
Finished goods
 
$
1,799
  
$
698
 
Raw materials
  
80
   
90
 
Packaging
  
130
   
110
 
Inventories
 
$
2,009
  
$
898
 
v3.20.2
LEASES (Tables)
6 Months Ended
Jun. 30, 2020
LEASES [Abstract]  
Components of Lease Expense
The components of lease expense and cash flows from leases (amounts in thousands) follow.

  
Three Months Ended June 30,
  
Six Months Ended June 30,
 
  
2020
  
2019
  
2020
  
2019
 
Finance lease cost:
            
Amortization of right-of use assets, included in cost of goods sold
 
$
20
  
$
14
  
$
41
  
$
18
 
Interest on lease liabilities
  
4
   
2
   
8
   
4
 
Operating lease cost, included in selling, general and administrative expenses:
                
Fixed leases cost
  
131
   
131
   
261
   
261
 
Variable lease cost
  
33
   
32
   
48
   
64
 
Short-term lease cost
  
-
   
7
   
3
   
16
 
Total lease cost
 
$
188
  
$
186
  
$
361
  
$
363
 
                 
Cash paid for amounts included in the measurement of lease liabilities:
                
Operating cash flows from finance leases
 
$
4
  
$
3
  
$
8
  
$
5
 
Operating cash flows from operating leases
 
$
131
  
$
131
  
$
261
  
$
261
 
Financing cash flows from finance leases
 
$
20
  
$
20
  
$
46
  
$
31
 
Remaining Lease Term and Discount Rate
The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of June 30, 2020, follows.

  
Operating
Leases
  
Finance
Leases
 
Remaining leases terms (in years)
  
3.3-12.7
   
0.6-4.0
 
Weighted average remaining lease terms (in years)
  
7.3
   
2.9
 
Discount rates
  
6.3%-9.0
%
  
4.3%-7.3
%
Weighted average discount rate
  
7.6
%
  
5.8
%
Maturities of Lease Liabilities
Maturities of lease liabilities as of June 30, 2020, follows (in thousands).

  
Operating
Leases
  
Finance
Leases
 
2020 (six months ended December 31, 2020)
 $
232
  $
62
 
2021
  
536
   
91
 
2022
  
548
   
68
 
2023
  
528
   
38
 
2024
  
428
   
11
 
Thereafter
  
1,469
   
-
 
Total lease payments
  
3,741
   
270
 
Amounts representing interest
  
(942
)
  
(24
)
Present value of lease obligations
 
$
2,799
  
$
246
 
v3.20.2
DEBT (Tables)
6 Months Ended
Jun. 30, 2020
DEBT [Abstract]  
Dues Under Factoring Agreement
Due under factoring agreement consists of the following (in thousands).

  
June 30,
2020
  
December 31,
2019
 
Borrowings outstanding
 
$
2,174
  
$
1,989
 
Debt issuance costs, net
  
(121
)
  
(166
)
Due under factoring agreement
 
$
2,053
  
$
1,823
 
Long-term Debt
Long-term debt consists of the following (in thousands).

  
June 30,
2020
  
December 31,
2019
 
Payroll Protection Program note - Dated April 2020.  Interest accrues at an annual rate of 1.0%.
      
Due in monthly installments from November 2020 to April 2022, unless forgiven as described below.
 
$
1,792
  $
-
 
Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year , which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition.  Payable in monthly installments. Expire at dates ranging through 2022.
  
47
   
62
 
Equipment note - Dated December 2019.  Due in monthly installments through December 2024.
        
Interest accrues at the effective discount rate of 9.3% per year .
  
37
   
39
 
Total long term debt
 
$
1,876
  
$
101
 
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)
6 Months Ended
Jun. 30, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]  
Equity Activity
A summary of equity activity follows (in thousands, except share amounts).

  
Shares
           
Accumulated
Other
    
  
Preferred
Series G
  
Common
  
Preferred
Stock
  
Common
Stock
  
Accumulated
Deficit
  
Comprehensive
Loss
  
Equity
 
Balance, December 31, 2019
  
225
   
40,074,483
  
$
112
  
$
318,811
  
$
(287,180
)
 
$
-
  
$
31,743
 
Common stock awards under equity incentive plans
  
-
   
17,534
   
-
   
312
   
-
   
-
   
312
 
Net loss
  
-
   
-
   
-
   
-
   
(3,033
)
  
-
   
(3,033
)
Balance, March 31, 2020
  
225
   
40,092,017
  
$
112
  
$
319,123
  
$
(290,213
)
 
$
-
  
$
29,022
 
Common stock awards under equity incentive plans
  
-
   
16,500
   
-
   
316
   
-
   
-
   
316
 
Commn stock issued to vendors
  
-
   
31,304
   
-
   
36
   
-
   
-
   
36
 
Exercise of common stock warrants
  
-
   
67,577
   
-
   
12
   
-
   
-
   
12
 
Other comprehensive loss
  
-
   
-
   
-
   
-
   
-
   
(48
)
  
(48
)
Net loss
  
-
   
-
   
-
   
-
   
(3,949
)
  
-
   
(3,949
)
Balance, June 30, 2020
  
225
   
40,207,398
  
$
112
  
$
319,487
  
$
(294,162
)
 
$
(48
)
 
$
25,389
 

  
Shares
          
  
Preferred
Series G
  
Common
  
Preferred
Stock
  
Common
Stock
  
Accumulated
Deficit
  
Equity
 
Balance, December 31, 2018
  
405
   
29,098,207
  
$
201
  
$
296,739
  
$
(273,229
)
 
$
23,711
 
Proceeds from sale of common stock and prefunded warrant, net of costs
  
-
   
3,046,668
   
-
   
11,593
   
-
   
11,593
 
Common stock awards under equity incentive plans
  
-
   
36,881
   
-
   
364
   
-
   
364
 
Exercise of common stock warrants
  
-
   
600,000
   
-
   
1,980
   
-
   
1,980
 
Conversion of preferred stock into common stock
  
(180
)
  
170,818
   
(89
)
  
89
   
-
   
-
 
Exercise of common stock options
  
-
   
77,078
   
-
   
60
   
-
   
60
 
Other
  
-
   
-
   
-
   
28
   
-
   
28
 
Net loss
  
-
   
-
   
-
   
-
   
(3,227
)
  
(3,227
)
Balance, March 31, 2019
  
225
   
33,029,652
   
112
   
310,853
   
(276,456
)
  
34,509
 
Exercise of prefunded warrant
  
-
   
1,003,344
   
-
   
10
   
-
   
10
 
Common stock awards under equity incentive plans
  
-
   
134,984
   
-
   
219
   
-
   
219
 
Exercise of common stock options
  
-
   
78,734
   
-
   
87
   
-
   
87
 
Other
  
-
   
-
   
-
   
32
   
-
   
32
 
Net loss
  
-
   
-
   
-
   
-
   
(3,659
)
  
(3,659
)
Balance, June 30, 2019
  
225
   
34,246,714
  
$
112
  
$
311,201
  
$
(280,115
)
 
$
31,198
 
Share-based Compensation by Type of Award
Share-based compensation by type of award follows (in thousands).

  
Three Months Ended
 
  
June 30, 2020
  
March 31, 2020
 
Common stock, vested at issuance and nonvested at issuance
 
$
95
  
$
105
 
Stock options
  
99
   
85
 
Restricted stock units
  
122
   
122
 
Compensation expense related to common stock awards issued under equity incentive plan
 
$
316
  
$
312
 
Stock Option Activity
Stock option activity for the six months ended June 30, 2020, follows.

  
Shares
Under
Options
   
Weighted
Average
Exercise
Price
  
Weighted
Average
Grant
Date Fair
Value
  
Weighted
Average
Remaining
Contractual
Life (Years)
 
Outstanding at December 31, 2019
  
996,009
  
$
3.23
      
8.1
 
Granted
  
653,004
   
1.22
  
$
0.73
   
10.0
 
Forfeited
  
(125,173
)
  
4.74
       
7.2
 
Outstanding at March 31, 2020
  
1,523,840
   
2.24
       
8.8
 
Forfeited
  
(77,357
)
  
4.28
       
7.2
 
Outstanding at June 30, 2020
  
1,446,483
  
$
2.13
       
8.6
 
RSU Activity
Restricted stock unit (RSU) activity for the six months ended June 30, 2020, follows.

  
RSU Shares
Issued to
Employees
and
Directors
  
Unrecognized
Stock
Compensation
(in thousands)
  
Weighted
Average
Expense
Period
(Years)
 
Nonvested at December 31, 2019
  
1,148,062
  
$
377
   
1.4
 
Cancelled
  
(625,000
)
  
-
     
Forfeited (1)
  
(175,000
)
  
(142
)
    
Expensed (2)
  
-
   
(122
)
    
Nonvested at March 31, 2020
  
348,062
   
113
   
1.2
 
Granted to Directors (3)
  
477,018
   
426
     
Forfeited
  
(30,000
)
  
(24
)
    
Vested (4)
  
(115,904
)
  
-
     
Expensed
  
-
   
(122
)
    
Nonvested at June 30, 2020 (5)(6)
  
679,176
  
$
393
   
0.8
 


(1)
In the three months ended March 31, 2020, we reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares.

(2)
We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares.

(3)
The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.

(4)
Represents shares of common stock subject to RSUs which were vested when granted.

(5)
RSUs for a total of 361,114 shares of common stock vest in June 2021, and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies.

(6)
A total of 318,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days.  Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 31,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 95,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 190,837 shares the date the vesting price equals or exceeds $15.00 per share.  Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence.  The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.
Warrant Activity
Warrant activity for the six months ended June 30, 2020, follows.

  
Shares
Under
Warrants
  
Weighted
Average
Exercise
Price
  
Weighted
Average
Remaining
Contractual
 Life (Years)
 
          
Outstanding, December 31, 2019
  
7,532,280
  
$
1.32
   
1.9
 
Expired
  
(265,000
)
  
5.25
   
-
 
Outstanding, March 31, 2020
  
7,267,280
   
1.18
   
1.7
 
Cash exercised
  
(12,948
)
  
0.96
   
-
 
Cashless exercised (1)
  
(215,740
)
  
0.96
   
-
 
Expired
  
(392,676
)
  
4.60
   
-
 
Outstanding, June 30, 2020 (2)
  
6,645,916
  
$
0.98
   
1.7
 


(1)
In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.

(2)
Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature.  As of June 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an average exercise price of $5.25 per share.  If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise.  If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.
v3.20.2
LOSS PER SHARE (EPS) (Tables)
6 Months Ended
Jun. 30, 2020
LOSS PER SHARE (EPS) [Abstract]  
Reconciliations of Numerators and Denominators in EPS Computations
Below are reconciliations of the numerators and denominators in the EPS computations.

  
Three Months Ended June 30
  
Six Months Ended June 30
 
  
2020
  
2019
  
2020
  
2019
 
NUMERATOR (in thousands):
            
Basic and diluted - loss from continuing operations
 
$
(3,949
)
 
$
(3,659
)
 
$
(6,982
)
 
$
(6,670
)
                 
DENOMINATOR:
                
Weighted average number of shares of shares of common stock outstanding
  
40,041,888
   
33,204,332
   
40,002,522
   
31,382,927
 
Weighted average number of shares of common stock underlying vested restricted stock units
  
10,275
   
-
   
5,138
   
-
 
Basic EPS - weighted average number of shares outstanding
  
40,052,163
   
33,204,332
   
40,007,660
   
31,382,927
 
Effect of dilutive securities outstanding
  
-
   
-
   
-
   
-
 
Diluted EPS - weighted average number of shares outstanding
  
40,052,163
   
33,204,332
   
40,007,660
   
31,382,927
 
v3.20.2
BUSINESS (Details)
Jun. 30, 2020
Location
BUSINESS [Abstract]  
Number of locations 4
Number of locations in California 2
Number of locations in Louisiana 1
v3.20.2
ACQUISITION (Details) - MGI Grain Processing LLC [Member] - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2019
Business Acquisition, Pro Forma Information [Abstract]    
Revenues $ 6,277 $ 13,783
Loss from continuing operations $ (3,803) $ (6,539)
Loss per share - continuing operations (in dollars per share) $ (0.11) $ (0.21)
Weighted average number of common shares outstanding - basic and diluted (in shares) 33,204,332 31,382,927
v3.20.2
CASH AND CASH EQUIVALENTS (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Jun. 30, 2019
Dec. 31, 2018
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 3,347 $ 8,444 $ 7,189 $ 7,044
Money Market Funds [Member]        
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 2,000      
v3.20.2
ACCOUNTS RECEIVABLE AND REVENUES (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Concentration of Credit Risk [Abstract]          
Revenues $ 5,903 $ 6,219 $ 14,233 $ 12,583  
Revenue unearned 0   $ 0   $ 12
Minimum [Member]          
Concentration of Credit Risk [Abstract]          
Receivables payment term     30 days    
Maximum [Member]          
Concentration of Credit Risk [Abstract]          
Receivables payment term     120 days    
Revenue unearned 100   $ 100    
Operating Segments [Member] | Food [Member]          
Concentration of Credit Risk [Abstract]          
Revenues 3,967 4,365 10,159 9,112  
Operating Segments [Member] | Animal Nutrition [Member]          
Concentration of Credit Risk [Abstract]          
Revenues $ 1,936 $ 1,854 $ 4,074 $ 3,471  
Customer A [Member] | Revenue [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage 10.00% 10.00% 9.00% 10.00%  
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage     14.00%   10.00%
Customer B [Member] | Revenue [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage 8.00% 14.00% 13.00% 16.00%  
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage     32.00%   31.00%
Customer C [Member] | Revenue [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage 3.00% 1.00% 2.00% 1.00%  
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage     8.00%   10.00%
v3.20.2
INVENTORIES (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Inventories [Abstract]    
Finished goods $ 1,799 $ 698
Raw materials 80 90
Packaging 130 110
Inventories $ 2,009 $ 898
v3.20.2
LEASES (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Finance lease cost [Abstract]        
Amortization of right-of use assets, included in cost of goods sold $ 20 $ 14 $ 41 $ 18
Interest on lease liabilities 4 2 8 4
Operating lease cost, included in selling, general and administrative expenses [Abstract]        
Fixed leases cost 131 131 261 261
Variable lease cost 33 32 48 64
Short-term lease cost 0 7 3 16
Total lease cost 188 186 361 363
Cash paid for amounts included in the measurement of lease liabilities [Abstract]        
Operating cash flows from finance leases 4 3 8 5
Operating cash flows from operating leases 131 131 261 261
Financing cash flows from finance leases 20 $ 20 46 $ 31
Finance lease right-of-use-assets, net $ 300   $ 300  
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] us-gaap:PropertyPlantAndEquipmentNet   us-gaap:PropertyPlantAndEquipmentNet  
Finance lease right-of-use-assets, original cost $ 400   $ 400  
Operating Leases [Abstract]        
Weighted average remaining lease terms (in years) 7 years 3 months 18 days   7 years 3 months 18 days  
Weighted average discount rate 7.60%   7.60%  
Finance Leases [Abstract]        
Weighted average remaining lease terms (in years) 2 years 10 months 24 days   2 years 10 months 24 days  
Weighted average discount rate 5.80%   5.80%  
Maturities of Operating Lease Liabilities [Abstract]        
2020 (six months ended December 31, 2020) $ 232   $ 232  
2021 536   536  
2022 548   548  
2023 528   528  
2024 428   428  
Thereafter 1,469   1,469  
Total lease payments 3,741   3,741  
Amounts representing interest (942)   (942)  
Present value of lease obligations 2,799   2,799  
Maturities of Finance Lease Liabilities [Abstract]        
2020 (six months ended December 31, 2020) 62   62  
2021 91   91  
2022 68   68  
2023 38   38  
2024 11   11  
Thereafter 0   0  
Total lease payments 270   270  
Amounts representing interest (24)   (24)  
Present value of lease obligations $ 246   $ 246  
Minimum [Member]        
Operating Leases [Abstract]        
Remaining leases terms (in years)     3 years 3 months 18 days  
Discount rate 6.30%   6.30%  
Finance Leases [Abstract]        
Remaining leases terms (in years)     7 months 6 days  
Discount rate 4.30%   4.30%  
Maximum [Member]        
Operating Leases [Abstract]        
Remaining leases terms (in years)     12 years 8 months 12 days  
Discount rate 9.00%   9.00%  
Finance Leases [Abstract]        
Remaining leases terms (in years)     4 years  
Discount rate 7.30%   7.30%  
v3.20.2
DEBT (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2020
Oct. 31, 2019
Jun. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Due under Factoring Agreement [Abstract]          
Due under factoring agreement     $ 2,053 $ 2,053 $ 1,823
Long-term Debt [Abstract]          
Total long-term debt     $ 1,876 $ 1,876 101
Minimum [Member]          
Debt Instruments [Abstract]          
Long term debt interest rate     4.70% 4.70%  
Interest rate     4.70% 4.70%  
Maximum [Member]          
Debt Instruments [Abstract]          
Long term debt interest rate     5.50% 5.50%  
Interest rate     5.50% 5.50%  
Factoring Agreement [Member]          
Due under Factoring Agreement [Abstract]          
Borrowing outstanding     $ 2,174 $ 2,174 1,989
Debt issuance costs, net     (121) (121) (166)
Due under factoring agreement     $ 2,053 $ 2,053 1,823
Factoring Agreement [Member] | Line of Credit [Member]          
Debt Instruments [Abstract]          
Line of credit facility, maximum borrowing capacity   $ 7,000      
Line of credit facility, initial term       2 years  
Facility fee, amount   $ 200      
Percentage of funding fee     0.50% 0.50%  
Interest and fees expense     $ 100 $ 200  
Fees incurred averaged percentage     4.40% 4.40%  
Interest averaged percentage     3.20% 3.20%  
Outstanding borrowings average amount     $ 2,900 $ 2,000  
Factoring Agreement [Member] | Line of Credit [Member] | Minimum [Member]          
Debt Instruments [Abstract]          
Line of credit facility, recurring fee   5.50%      
Factoring Agreement [Member] | Line of Credit [Member] | Maximum [Member]          
Debt Instruments [Abstract]          
Amortization of debt issuance costs     $ 100 $ 100  
Paycheck Protection Program [Member] | Notes Payable [Member]          
Debt Instruments [Abstract]          
Long term debt interest rate     1.00% 1.00%  
Maturity date of note start       Nov. 30, 2020  
Maturity date of note end       Apr. 30, 2022  
Interest rate     1.00% 1.00%  
Long-term Debt [Abstract]          
Total long-term debt     $ 1,792 $ 1,792 0
Equipment Notes, November 2018 [Member] | Notes Payable [Member]          
Debt Instruments [Abstract]          
Long term debt interest rate     4.80% 4.80%  
Maturity date       Dec. 31, 2022  
Interest rate     4.80% 4.80%  
Long-term Debt [Abstract]          
Total long-term debt     $ 47 $ 47 62
Equipment Notes, December 2019 [Member] | Notes Payable [Member]          
Debt Instruments [Abstract]          
Long term debt interest rate     9.30% 9.30%  
Maturity date       Dec. 31, 2024  
Interest rate     9.30% 9.30%  
Long-term Debt [Abstract]          
Total long-term debt     $ 37 $ 37 $ 39
Mortgage Agreement [Member]          
Debt Instruments [Abstract]          
Maturity date Jun. 30, 2022        
Mortgage Agreement [Member] | Subsequent Event [Member]          
Debt Instruments [Abstract]          
Long term debt interest rate 14.30%        
Line of credit facility, maximum borrowing capacity $ 2,000        
Maximum percentage of credit facility available on appraised value of real property 65.00%        
Interest rate 14.30%        
Credit facility fee percentage on amount of each advance 1.00%        
Mortgage Agreement [Member] | Minimum [Member] | Subsequent Event [Member] | Prime Rate [Member]          
Debt Instruments [Abstract]          
Accrued interest on borrowings at annual rate 11.00%        
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Summary of Equity Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
May 31, 2020
Dec. 31, 2019
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]                
Common stock, shares authorized (in shares) 150,000,000       150,000,000   50,000,000 150,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance $ 29,022 $ 31,743 $ 34,509 $ 23,711 $ 31,743 $ 23,711    
Balance (in shares)   40,074,483     40,074,483      
Proceeds from sale of common stock and prefunded warrant, net of costs       11,593        
Exercise of Prefunded Warrant     10          
Common stock awards under equity incentive plans 316 $ 312 219 364        
Common stock issued to vendors 36              
Exercise of common stock warrants 12     1,980        
Conversion of preferred stock into common stock       0        
Exercise of common stock options     87 60        
Other     32 28        
Other comprehensive loss (48)   0   $ (48) 0    
Net loss (3,949) (3,033) (3,659) (3,227) (6,982) (6,886)    
Balance $ 25,389 29,022 31,198 34,509 $ 25,389 31,198    
Balance (in shares) 40,207,398       40,207,398      
Preferred Stock [Member]                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance $ 112 112 112 201 $ 112 201    
Proceeds from sale of common stock and prefunded warrant, net of costs       0        
Exercise of Prefunded Warrant     0          
Common stock awards under equity incentive plans 0 0 0 0        
Common stock issued to vendors 0              
Exercise of common stock warrants 0     0        
Conversion of preferred stock into common stock       (89)        
Exercise of common stock options     0 0        
Other     0 0        
Other comprehensive loss 0              
Net loss 0 0 0 0        
Balance $ 112 $ 112 $ 112 $ 112 $ 112 $ 112    
Preferred Stock [Member] | Series G Preferred Stock [Member]                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance (in shares) 225 225 225 405 225 405    
Proceeds from sale of common stock and prefunded warrant, net of costs (in shares)       0        
Exercise of Prefunded Warrant (in shares)     0          
Common stock awards under equity incentive plans (in shares) 0 0 0 0        
Common stock issued to vendors (in shares) 0              
Exercise of common stock warrants (in shares) 0     0        
Conversion of preferred stock into common stock (in shares)       (180)        
Exercise of common stock options (in shares)     0 0        
Other (in shares)     0 0        
Balance (in shares) 225 225 225 225 225 225    
Common Stock [Member]                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance $ 319,123 $ 318,811 $ 310,853 $ 296,739 $ 318,811 $ 296,739    
Balance (in shares) 40,092,017 40,074,483 33,029,652 29,098,207 40,074,483 29,098,207    
Proceeds from sale of common stock and prefunded warrant, net of costs       $ 11,593        
Proceeds from sale of common stock and prefunded warrant, net of costs (in shares)       3,046,668        
Exercise of Prefunded Warrant     $ 10          
Exercise of Prefunded Warrant (in shares)     1,003,344          
Common stock awards under equity incentive plans $ 316 $ 312 $ 219 $ 364        
Common stock awards under equity incentive plans (in shares) 16,500 17,534 134,984 36,881        
Common stock issued to vendors $ 36              
Common stock issued to vendors (in shares) 31,304              
Exercise of common stock warrants $ 12     $ 1,980        
Exercise of common stock warrants (in shares) 67,577     600,000        
Conversion of preferred stock into common stock       $ 89        
Conversion of preferred stock into common stock (in shares)       170,818        
Exercise of common stock options     $ 87 $ 60        
Exercise of common stock options (in shares)     78,734 77,078        
Other     $ 32 $ 28        
Other (in shares)     0 0        
Other comprehensive loss $ 0              
Net loss 0 $ 0 $ 0 $ 0        
Balance $ 319,487 $ 319,123 $ 311,201 $ 310,853 $ 319,487 $ 311,201    
Balance (in shares) 40,207,398 40,092,017 34,246,714 33,029,652 40,207,398 34,246,714    
Accumulated Deficit [Member]                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance $ (290,213) $ (287,180) $ (276,456) $ (273,229) $ (287,180) $ (273,229)    
Proceeds from sale of common stock and prefunded warrant, net of costs       0        
Exercise of Prefunded Warrant     0          
Common stock awards under equity incentive plans 0 0 0 0        
Common stock issued to vendors 0              
Exercise of common stock warrants 0     0        
Conversion of preferred stock into common stock       0        
Exercise of common stock options     0 0        
Other     0 0        
Other comprehensive loss 0              
Net loss (3,949) (3,033) (3,659) (3,227)        
Balance (294,162) (290,213) $ (280,115) $ (276,456) (294,162) $ (280,115)    
Accumulated Other Comprehensive Loss [Member]                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance 0 0     0      
Common stock awards under equity incentive plans 0 0            
Common stock issued to vendors 0              
Exercise of common stock warrants 0              
Other comprehensive loss (48)              
Net loss 0 0            
Balance $ (48) $ 0     $ (48)      
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Sales Agreement (Details) - At-the-Market Offering [Member]
$ in Millions
Mar. 30, 2020
USD ($)
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]  
Deferred offering costs, legal expenses and other costs $ 0.1
Maximum [Member]  
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]  
Aggregate offering price of common stock $ 6.0
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Share-Based Compensation by Type of Award (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Share-based compensation expense [Abstract]        
Compensation expense related to common stock awards issued under equity incentive plan $ 316 $ 312    
Common Stock [Member]        
Share-based compensation expense [Abstract]        
Compensation expense related to common stock awards issued under equity incentive plan $ 100      
Common Stock Issued under Equity Incentive Plans [Abstract]        
Shares issued (in shares) 16,500 17,534 134,984 36,881
Grant date fair value (in dollars per share) $ 1.16      
Nonvested common stock outstanding (in shares) 0      
Common Stock [Member] | Consultant [Member]        
Share-based compensation expense [Abstract]        
Compensation expense related to common stock awards issued under equity incentive plan   $ 100    
Common Stock Issued under Equity Incentive Plans [Abstract]        
Shares issued (in shares)   17,534    
Grant date fair value (in dollars per share)   $ 1.11    
Common Stock [Member] | Vendor [Member]        
Common Stock Issued under Equity Incentive Plans [Abstract]        
Shares issued (in shares) 31,304      
Grant date fair value (in dollars per share) $ 1.14      
Common Stock, Vested at Issuance and Nonvested at Issuance [Member]        
Share-based compensation expense [Abstract]        
Compensation expense related to common stock awards issued under equity incentive plan $ 95 $ 105    
Stock Options [Member]        
Share-based compensation expense [Abstract]        
Compensation expense related to common stock awards issued under equity incentive plan 99 85    
Restricted Stock Units [Member]        
Share-based compensation expense [Abstract]        
Compensation expense related to common stock awards issued under equity incentive plan $ 122 $ 122    
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Stock Options (Details) - Stock Options [Member] - $ / shares
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2020
Dec. 31, 2019
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]        
Options exercisable period     4 years  
Shares Under Options, Outstanding [Roll Forward]        
Outstanding at beginning of period (in shares) 1,523,840 996,009 996,009  
Granted (in shares)   653,004    
Forfeited (in shares) (77,357) (125,173)    
Outstanding at end of period (in shares) 1,446,483 1,523,840 1,446,483 996,009
Options, Weighted Average Exercise Price [Roll Forward]        
Outstanding at beginning of period (in dollars per share) $ 2.24 $ 3.23 $ 3.23  
Granted (in dollars per share)   1.22    
Forfeited (in dollars per share) 4.28 4.74    
Outstanding at end of period (in dollars per share) $ 2.13 2.24 $ 2.13 $ 3.23
Options, Weighted Average Grant Date Fair Value [Abstract]        
Granted (in dollars per share)   $ 0.73    
Options, Weighted Average Remaining Contractual Life [Abstract]        
Outstanding, weighted average remaining contractual life 8 years 7 months 6 days 8 years 9 months 18 days   8 years 1 month 6 days
Granted   10 years    
Forfeited 7 years 2 months 12 days 7 years 2 months 12 days    
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Restricted Stock Units (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2020
Dec. 31, 2019
Jun. 30, 2020
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Share-based compensation expense recognized $ 316 $ 312      
Restricted Stock Units [Member]          
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Share-based compensation expense reversal on forfeited shares   100      
Share-based compensation expense recognized $ 122 $ 122      
Restricted Stock Units [Member] | Minimum [Member]          
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Award vesting period 1 year        
Restricted Stock Units [Member] | Maximum [Member]          
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Award vesting period 5 years        
Restricted Stock Units [Member] | Employee and Director [Member]          
Restricted Stock Award Activity, Number [Roll Forward]          
Beginning balance, Nonvested (in shares) 348,062 1,148,062 1,148,062    
Granted to director (in shares) [1] 477,018        
Cancelled (in shares)   (625,000)      
Forfeited (in shares) (30,000) (175,000) [2]      
Vested (in shares) [3] (115,904)        
Ending balance, Nonvested (in shares) 679,176 [4],[5] 348,062 679,176 [4],[5] 1,148,062  
Unrecognized Stock Compensation [Abstract]          
Unrecognized stock compensation $ 113 $ 377 $ 377    
Granted to director [1] 426        
Cancelled   0      
Vested [3] 0        
Expensed (122) (122) [6]      
Forfeited (24) (142) [2]      
Unrecognized stock compensation $ 393 [4],[5] $ 113 $ 393 [4],[5] $ 377  
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Weighted average expense period (Years) 9 months 18 days [4],[5] 1 year 2 months 12 days   1 year 4 months 24 days  
Nonvested shares (in shares) 679,176 [4],[5] 348,062 679,176 [4],[5] 1,148,062 679,176 [4],[5]
Restricted Stock Units [Member] | Director [Member] | Maximum [Member]          
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Award vesting period     1 year    
Vesting June 2021 [Member] | Restricted Stock Units [Member]          
Restricted Stock Award Activity, Number [Roll Forward]          
Ending balance, Nonvested (in shares) 361,114   361,114    
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Nonvested shares (in shares) 361,114   361,114   361,114
Vesting Price Equal to Volume Weighted Average Trading Price of Common Stock [Member] | Restricted Stock Units [Member]          
Restricted Stock Award Activity, Number [Roll Forward]          
Ending balance, Nonvested (in shares) 318,062   318,062    
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Number of trading days     65 days    
Nonvested shares (in shares) 318,062   318,062   318,062
Vesting Price Equals or Exceeds $5.00 [Member] | Restricted Stock Units [Member]          
Restricted Stock Award Activity, Number [Roll Forward]          
Ending balance, Nonvested (in shares) 31,806   31,806    
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Nonvested shares (in shares) 31,806   31,806   31,806
Vesting price (in dollars per share)         $ 5.00
Vesting Price Equals or Exceeds $10.00 [Member] | Restricted Stock Units [Member]          
Restricted Stock Award Activity, Number [Roll Forward]          
Ending balance, Nonvested (in shares) 95,419   95,419    
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Nonvested shares (in shares) 95,419   95,419   95,419
Vesting price (in dollars per share)         $ 10.00
Vesting Price Equals or Exceeds $15.00 [Member] | Restricted Stock Units [Member]          
Restricted Stock Award Activity, Number [Roll Forward]          
Ending balance, Nonvested (in shares) 190,837   190,837    
Weighted Average Remaining Vesting and Expense Period [Abstract]          
Nonvested shares (in shares) 190,837   190,837   190,837
Vesting price (in dollars per share)         $ 15.00
[1] The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.
[2] In the three months ended March 31, 2020, we reversed $0.1 million of expense recognized prior to January 1, 2020 on forfeited RSU shares.
[3] Represents shares of common stock subject to RSUs which were vested when granted.
[4] A total of 318,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 31,806 shares on the date the vesting price equals or exceeds $5.00 per share (ii) 95,419 shares the date the vesting price equals or exceeds $10.00 per share and (iii) 190,837 shares the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.
[5] RSUs for a total of 361,114 shares of common stock vest in June 2021, and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies
[6] We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares.
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrants Activity (Details) - Warrants [Member] - $ / shares
3 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Shares Under Warrants [Roll Forward]      
Outstanding at beginning of period (in shares) 7,267,280 7,532,280  
Cash exercised (in shares) (12,948)    
Cashless exercised (in shares) [1] (215,740)    
Expired (in shares) (392,676) (265,000)  
Outstanding at end of period (in shares) 6,645,916 [2] 7,267,280 7,532,280
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]      
Outstanding at beginning of period (in dollars per share) $ 1.18 $ 1.32  
Cash exercised (in dollars per share) 0.96    
Cashless exercised (in dollars per share) 0.96    
Expired (in dollars per share) 4.60 5.25  
Outstanding at end of period (in dollars per share) $ 0.98 [2] $ 1.18 $ 1.32
Warrants, Additional Disclosures [Abstract]      
Outstanding, weighted average remaining contractual life 1 year 8 months 12 days 1 year 8 months 12 days 1 year 10 months 24 days
Issuance of common stock upon cashless exercise of warrants (in shares) 54,629    
Warrants under cashless exercise feature 7,267,280 7,267,280 7,532,280
Weighted average exercise price (in dollars per share) $ 1.18 $ 1.18 $ 1.32
$0.96 [Member]      
Shares Under Warrants [Roll Forward]      
Outstanding at end of period (in shares) 3,484,675    
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]      
Outstanding at end of period (in dollars per share) $ 0.96    
Warrants, Additional Disclosures [Abstract]      
Warrants under cashless exercise feature 3,484,675    
Weighted average exercise price (in dollars per share) $ 0.96    
$5.25 [Member]      
Shares Under Warrants [Roll Forward]      
Outstanding at end of period (in shares) 25,000    
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]      
Outstanding at end of period (in dollars per share) $ 5.25    
Warrants, Additional Disclosures [Abstract]      
Warrants under cashless exercise feature 25,000    
Weighted average exercise price (in dollars per share) $ 5.25    
[1] In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.
[2] Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. As of June 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an average exercise price of $5.25 per share. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.
v3.20.2
LOSS PER SHARE (EPS) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
NUMERATOR [Abstract]        
Basic and diluted - loss from continuing operations $ (3,949) $ (3,659) $ (6,982) $ (6,670)
DENOMINATOR [Abstract]        
Weighted average number of shares of shares of common stock outstanding (in shares) 40,041,888 33,204,332 40,002,522 31,382,927
Weighted average number of shares of common stock underlying vested restricted stock units (in shares) 10,275 0 5,138 0
Basic EPS - weighted average number of shares outstanding (in shares) 40,052,163 33,204,332 40,007,660 31,382,927
Effect of dilutive securities outstanding (in shares) 0 0 0 0
Diluted EPS - weighted average number of shares outstanding (in shares) 40,052,163 33,204,332 40,007,660 31,382,927
v3.20.2
DERIVATIVE FINANCIAL INSTRUMENTS (Details)
$ in Thousands
Jun. 30, 2020
USD ($)
Derivative, Fair Value, Net [Abstract]  
Fair value of open futures recorded in Accumulated OCI $ (48)
Credit risk associated with open derivative financial instruments 0
Other Current Assets [Member]  
Derivative, Fair Value, Net [Abstract]  
Derivative receivable $ 500
v3.20.2
FAIR VALUE MEASUREMENTS (Details)
$ in Millions
Jun. 30, 2020
USD ($)
Level 3 [Member]  
Fair Value Measurements [Abstract]  
Fair value of operating leases liabilities $ 0.1
v3.20.2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2020
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Legal Matters [Abstract]            
Cost of goods sold   $ 7,127 $ 6,463 $ 15,862 $ 12,484  
Amount of liability   9,952   9,952   $ 8,749
Legal Matters [Member]            
Legal Matters [Abstract]            
Cost of goods sold   200        
Amount of liability   $ 200   $ 200    
Subsequent Event [Member] | Legal Matters [Member]            
Legal Matters [Abstract]            
Amount of contract dispute settlement $ 200          
v3.20.2
RELATED PARTY TRANSACTIONS (Details)
3 Months Ended 6 Months Ended
Mar. 31, 2019
$ / shares
shares
Jun. 30, 2020
Nominee
$ / shares
Minimum [Member]    
Related Party Transaction Information [Abstract]    
Ownership percentage   19.99%
Ari Gendason [Member] | Continental Grain Company [Member]    
Related Party Transaction Information [Abstract]    
Ownership interest percentage   26.50%
Sale of common stock (in shares) | shares 666,667  
Share price (in dollars per share) $ 3.00  
Exercise price per warrant (in dollars per share)   $ 0.01
Number of nominee for the Board of Directors related party can designate | Nominee   1
Ari Gendason [Member] | Continental Grain Company [Member] | Private Placement [Member]    
Related Party Transaction Information [Abstract]    
Shares callable by Prefunded Warrant (in shares) | shares 1,003,344  
Share price (in dollars per share) $ 2.99  
v3.20.2
TRANSACTIONS WITH EMPLOYEES (Details) - Wayne Wilkison [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 31, 2019
Jun. 30, 2019
Jun. 30, 2020
Dec. 31, 2019
Employee Transaction [Abstract]        
Amount paid to related parties $ 1.4 $ 1.4    
Amounts payable to entities     $ 0.0 $ 0.0
v3.20.2
SUBSEQUENT EVENTS (Details)
Aug. 11, 2020
Subsequent Event [Member] | Peter G. Bradley [Member] | Minimum [Member]  
Subsequent Events [Abstract]  
Number of years experience as an executive 23 years